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ABSTRACT OF THE DISSERTATION 
 
Taspase1 is a non-oncogene mediator of tumorigenesis and maintenance 
 
by 
 
David Yuan-Sou Chen 
 
Doctor of Philosophy in Biology and Biomedical Sciences 
 
Molecular Cell Biology 
 
Washington University in St. Louis, 2012 
 
Asst. Professor James Hsieh, Chairperson 
 
The clinical success of oncogene-targeted therapies substantiates the continued reliance of 
certain cancers upon the continued function of apical oncogenes involved in its genesis—a 
phenomenon known as “oncogene addiction.”  Though this shift from non-targeted, cytotoxic 
therapies offers new hope to patients, resistance to oncogene inactivation often remains an 
eventuality, and it is clear that further investigation is required to more effectively battle cancer 
using alternative therapeutic targets.  Our studies on Taspase1 (threonine aspartase 1) reveal its 
role in coordinating cellular proliferation and apoptosis in cancer.  Loss of Taspase1 by shRNA-
mediated knockdown decreased cellular proliferation in a diverse set of cancer cell lines, 
including glioblastoma, melanoma, lung, breast, colon, and prostate, as well as increased 
sensitivity to death stimuli in melanoma and glioblastoma.  Taspase1 loss impedes proliferation 
via up-regulation of the Cyclin dependent kinase inhibitor p27 and destabilizes the anti-apoptotic 
BCL-2 family member MCL-1.  Decreased levels of MCL-1 in glioblastoma and melanoma due to 
Taspase1 loss sensitizes these cells to a variety of apoptotic stimuli, including anoikis, DNA 
damaging agents etoposide and doxorubicin, and to a targeted inhibitor of BCL-2 family proteins, 
ABT-737.  We found that Taspase1 is over-expressed in multiple primary human tumors, 
including glioblastoma and melanoma, suggesting that Taspase1 is relevant to tumorigenesis in 
humans and that its inhibition could be clinically useful. 
 
In vitro examination of tumorigenic clones selected by their ability to form colonies in soft agar 
revealed an increase in Taspase1 expression compared to the unselected pool of MEFs 
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transduced by defined oncogenes, suggesting an increased reliance on Taspase1 in the process 
of tumorigenic transformation.  Yet, we demonstrate that Taspase1 is not an oncogene, and 
therefore, Taspase1 better fits a new class of cancer targets—the subordinate cellular machinery 
of oncogene-driven processes.  Dependence on this machinery was recently termed “non-
oncogene addiction.”  Taspase1 loss can sensitize cancer cells to both cytotoxic agents as well 
as oncogene-targeted agents, suggesting that inhibition of the non-oncogene addiction protease 
Taspase1 can complement traditional therapies.   
 
Through high throughput screening, we have identified a noncompetitive, small molecule inhibitor 
of Taspase1, named TASPIN-1, which inhibits Taspase1 in vitro and in cell culture.  Murine 
fibroblasts treated with TASPIN-1 exhibit decreased proliferative capacity, while also 
demonstrating molecular characteristics similar to those observed with the acute, genetic loss of 
Taspase1.  TASPIN-1 treatment exerts specific cytotoxicity in human breast cancer and 
glioblastoma cells that have high expression of Taspase1.  Additionally, TASPIN-1 treated mice 
bearing U251 human glioblastoma xenografts exhibit tumor regression while the mice tolerated 
short term treatment relatively well.  This suggests that pharmacological inhibition of Taspase1 is 
of potential therapeutic benefit in the treatment of cancer patients. 
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Chapter 1 
 
Oncogenesis, tumor suppression, and Taspase1 
 
 
1.1 Cancer is a balance between oncogene signaling and suppressed tumor 
suppression 
 
1.2 Addiction to oncogene signaling pathways in cancer 
 
1.3 Taspase1 is an evolutionarily conserved threonine protease required for 
proper embryonic development and cellular proliferation 
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1.1 Cancer is a balance between oncogene signaling and suppressed tumor suppression 
 
Cancer phenotypes codified 
Cancer is a phenotypic manifestation of genetic and epigenetic alterations that are adaptive for 
the cell but maladaptive, ultimately, for the host.  Cellular alterations that give rise to cancer are 
multitudinous, particularly between cancers of different tissue origins but also within the same 
cancer subtype.  Despite the diversity of molecular alterations, the phenotypic expression of 
malignancy has been codified into discreet hallmarks, including the ability to propagate 
independent of growth factor signaling, resistance against cell death, limitless replicative 
potential, insensitivity to growth-inhibitory signals, sustained angiogenesis, and metastasis 
(Hanahan and Weinberg, 2000).  It seems, then, that the common goal of these traits, whether 
intrinsic to the cancer cell or extrinsic, lies in support for the continued potential for deregulated 
growth and survival of cancer, except in metastasis.  Though successful metastasis—from 
migration from the primary tumor to intravasation and survival in the blood, extravasation, and 
survival in the end organ—is not of prima facie benefit to the malignant cell, the fact is that at 
terminal stage, cancers typically exhibit metastatic character.  One might hypothesize, then, that 
the ability to metastasize is merely an incidental manifestation of alterations that were selected for 
on the basis that they are critical to tumor growth.  Recent evidence suggests that this is indeed 
the case in breast cell lines which depend on a set of genes to support tumor growth as well as 
vascular remodeling (Gupta et al., 2007).  It is increasingly clear that the common theme to these 
phenotypic hallmarks of cancer, then, is the molecular alterations that underlie them.  These 
alterations are typically classified in two groups—genetic or epigenetic changes in certain genes 
drive various aspects of oncogenic processes, while the loss or alteration of function of other 
genes required for cellular homeostasis facilitates the oncogenic transformation processes.  
These genes are known as oncogenes and tumor suppressors, respectively, and they are of 
critical importance to tumorigenesis and tumor maintenance.  Yet, this body of work demonstrates 
that Taspase1, which is not an oncogene, is also of critical importance to tumor maintenance. 
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Experimental determination of oncogenic potential 
The genetic origins of cancer had been postulated by Theodore Boveri in conclusions drawn from 
his work on sea urchins: 
 
A malignant tumor cell is—and here again I take up the ideas of  
Hansemann—a cell with a specific abnormal chromosome constitution. (Harris, 
2008) 
 
And of proto-oncogenes: 
 
However, the hypothesis that there are chromosomes that stimulate cell 
multiplication is also compatible with our proposal.  In this view, cell division 
would take place when the operation of the stimulatory region of the chromatin, 
normally too weak, is enhanced by some active agent. The unrestrained 
proliferation of malignant tumour cells would then be due to a permanent excess 
of these stimulatory chromosomes. (Harris, 2008) 
 
Though these ideas were introduced in 1914, they had remarkable bearing on the ensuing 
discovery of oncogenes, illuminated by much work done in retroviral oncogenesis, which was 
subsequently extended to cellular oncogenes (Bishop, 1983).  Many other oncogenes were 
identified through a combination of retroviral insertional mutagenesis as well as transfection of 
tumor-derived DNA into the immortalized murine fibroblast line NIH/3T3.  This, notably, led to the 
discovery of the human RAS oncogene from bladder cancer (Shih and Weinberg, 1982), formally 
linking the previous retroviral oncogene work with the establishment of human cellular oncogenes 
(Der et al., 1982; Parada et al., 1982; Santos et al., 1982).  The importance of oncogenic RAS 
was substantiated by later findings that human tumors bear RAS mutations primarily in codons 
12, 13, or 61, rendering its GTPase ability constitutively active.  RAS was found to be mutated in 
a wide spectrum of cancers, with the highest frequency in exocrine pancreas (80% bear KRAS 
mutations), though many other tumor types also exhibit a high frequency of RAS mutation, 
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including lung, colon, and thyroid adenocarcinoma, as well as NRAS mutations in myeloid 
leukemias (Bos, 1989). 
 
RAS was found to be regulated by upstream factors like receptor tyrosine kinases, which are 
known to be oncogenes as well, including the epidermal growth factor receptor (Kamata and 
Feramisco, 1984; Mulcahy et al., 1985) and the related HER2/neu.  Both receptors were defined 
as oncogenes by their ability to cause morphological transformation of NIH/3T3 cells as well as 
their ability to confer anchorage independent growth to these cells in soft agar assays and tumor 
formation when allografted in immunodeficient mice (Di Fiore et al., 1987; Hudziak et al., 1987; 
Velu et al., 1987) .  In these studies, soft agar growth correlated well with tumor formation upon 
injection into mice likely because soft agar growth reflects many of the growth and survival 
advantages acquired in the transformation process.  This includes the ability to survive 
independently of signals provided by ligation of homotypic and heterotypic adhesion receptors, 
without which typically initiates a physiological death stimulus known as anoikis (Frisch and 
Francis, 1994).  Such a strong correlation—that soft agar growth always correlates with in vivo 
tumor growth—from a seemingly simple assay belies the complexity of oncogene signaling and 
the transformed phenotype.  Indeed, RAS provides signals to regulate cellular proliferation, death 
and survival, protein translation, and cellular motility through its multiple effector pathways RAF, 
RAL-GDS and PI3K (Downward, 2003; Malumbres and Barbacid, 2003). 
 
Despite the complexity of RAS signaling alone and the current knowledge that upstream growth 
factor signals regulate more proto-oncogenes than just RAS (for example, the 
phosphotidylinositol-3-kinase, PI3K, proto-oncogene), it has been shown that activated RAS 
alone cannot transform primary murine fibroblasts.  Rather, at least two oncogenic changes are 
necessary for murine transformation.  Additionally, these alterations must be complementary 
(Land et al., 1983), as RAS alone can interact with other oncogenic pathways, including the direct 
activation of the PI3K pathway (Rodriguez-Viciana et al., 1994; Sjolander et al., 1991). 
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RAS and MYC comprise one such pair of complementary oncogenes (Land et al., 1983).  MYC is 
a strongly mitogenic oncogene and has a very short halflife, while co-expression of activated RAS 
can stabilize MYC levels.  This results in MAPK dependent phosphorylation of MYC and 
subsequent E2F2-mediated transcription and Cyclin E/cdk2 activation, which leads ultimately to 
S-phase entry (Leone et al., 1997; Sears et al., 1999; Sears et al., 2000).  Cooperation between 
MYC and RAS, however, extends beyond stabilization of MYC and enhanced proliferation driven 
by oncogenic RAS and MYC. 
 
Oncogenes elicit tumor suppressive signals   
Three key barriers to tumorigenesis are irreversible growth arrest (senescence), cell death, and 
differentiation.  Deregulation of proto-oncogenes like MYC and RAS enhance the tumorigenic 
capabilities of the nascent cancer cell; however, tumor suppressive mechanisms can counteract 
aberrant, oncogenic signals.  Ectopic expression of either MYC or activated RAS alone is not only 
unable to transform primary murine cells, the overwhelming oncogenic signaling is actually 
deleterious to cells.  RAS over-expression induces p53 and p16INK4A tumor suppressor expression 
and cellular senescence in vitro, and BRAFE600 expression in melanocytes induces senescence in 
vivo, as seen in growth-arrested benign nevi from patients (Michaloglou et al., 2005; Serrano et 
al., 1997).  The degree to which tumor suppression is elicited seems to be dose-dependent.  
Increased MAPK/ERK signaling through RAF activation induces cell cycle arrest that depends on 
the expression of the Cyclin-dependent kinase inhibitor (CDKI) p21CIP1 (Woods et al., 1997).  
Titration of oncogenic RAS from a mammary specific promoter reveals that high levels of RAS 
signaling in vivo results in transient increases in proliferation in breast epithelium with an ensuing 
senescence that is dependent on the INK4A/ARF locus.  Low level RAS signaling can escape 
p53 activation as well as activation of INK4A/ARF locus, while maintaining enhanced proliferation.  
Tumors formed by low-level RAS activation exhibited additional up-regulation of endogenous 
RAS as well as evasion of tumor suppressive signals, with p53 loss of heterozygosity and failure 
of INK4A/ARF induction (Sarkisian et al., 2007).   
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MYC expression, in normal cell cycle, is very tightly regulated as quiescent cells have 
undetectable MYC expression; however, upon mitogenic stimuli, MYC is transcribed and can 
promote S-phase entry by a variety of mechanisms, including directly activating Cyclin D2 and 
CDK4, activating CyclinE/ckd2, indirectly down-regulating p27KIP1, and directly down-regulating 
p21CIP1 and p15INK4B (Pelengaris et al., 2002a).  Supraphysiological expression of MYC, however, 
is a potent inducer of apoptosis (Evan et al., 1992)—an effect which relies on the activation of the 
p53 pathway through p19ARF-mediated stabilization, or the induction of pro-apoptotic BH3-only 
molecule BIM (Adhikary and Eilers, 2005).  Deregulation of the p53 pathway, or mutation of 
residues in MYC that are required for BIM induction, facilitate MYC-induced lymphomagenesis 
(Eischen et al., 1999; Hemann et al., 2005).  Expression of anti-apoptotic BCL-2 family members 
counteracts MYC-induced apoptosis in vitro and facilitates tumorigenesis in vivo (Beverly and 
Varmus, 2009; Fanidi et al., 1992; Pelengaris et al., 2002b). 
 
Together, evasion of homeostatic tumor suppressor mechanisms as well as promotion of 
tumorigenic signaling is likely to form the basis for the cooperation of oncogenes in oncogene 
complementation or with tumor suppressor inactivation.  Though RAS can serve to prevent 
apoptosis initiated by MYC over-expression through activation of PI3K/AKT (Kauffmann-Zeh et 
al., 1997), in the context of Cyclin D1, D2, and D3 triple deficiency, MYC and RAS are not able to 
efficiently complement each other, presumably because an important pro-mitogenic arm is lost.  
This suggests that prevention of apoptosis alone is not sufficient to generate tumors and 
highlights the necessary function of cooperating oncogenes to both disarm tumor suppressors as 
well as provide proliferative signals (Kozar et al., 2004). 
 
Oncogene-induced tumor suppressive mechanisms, like apoptosis and senescence, act as a 
barrier for tumor evolution because these endpoints are achievable through the same oncogenic 
signals that drive tumorigenesis, depending on the context in which they occur (Lowe et al., 
2004).  Though there was little question whether apoptosis was a tumor suppressive mechanism, 
senescence was only more recently established as a bona fide antitumor mechanism in vivo 
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(Braig et al., 2005; Chen et al., 2005b; Michaloglou et al., 2005).  That efficient tumorigenesis 
from oncogenes requires complementary deactivation of tumor suppressive pathways illuminates 
the intrinsic failsafe mechanisms that have evolved in multi-cellular organisms to maintain 
homeostasis.  Indeed, it is these intrinsic failsafe mechanisms that we are attempting to engage 
when treating cancer. 
 
Revealing the complexity of cancer 
The scope of mutations characterized in cancers is rapidly increasing as we overcome 
technological hurdles.  Massive sequencing projects have recently identified many mutations in 
various cancers.  Exonic sequencing in lung cancer revealed more than 1,000 somatic mutations 
across 623 genes, with 26 occurring at high frequency (Ding et al., 2008).  Subsequent efforts to 
look globally at mutations encompassed the entire genome in samples from patients with 
leukemia as well as in human cancer cell lines.  This has led to some interesting insights 
regarding the number of total mutations in cancer cells as well as how many are intragenic versus 
intergenic (Ding et al., 2010; Jones et al., 2008; Ley et al., 2008; Parsons et al., 2008; Pleasance 
et al., 2010a; Pleasance et al., 2010b).  In the sequencing of cytogenetically normal M1 AML 
(~10% of all cases of AML), the number of mutations in gene coding regions that were non-
synonymous and unique to the tumor was surprisingly few—10 mutations, of which the majority of 
genes had no described function in AML pathogenesis.  Furthermore, not all of the mutated 
genes were detectably expressed in the tumor (Ley et al., 2008).  However, the total tumor-
specific single nucleotide variants (SNVs) in intergenic sequences was on the order of tens of 
thousands, and using normal skin as a control renders germline predisposition mutations virtually 
undetectable.  Though studying the gene-coding mutations is likely to have the highest yield in 
the short term, these studies highlight the intricacy of how one determines which mutations drive 
oncogenesis and which ones are incidental; in short, it is possible that nongenic mutations play a 
critical role in tumorigenesis.  These issues will likely be addressed as sequencing and analysis 
technologies advance, and when all mutations in all tumors can be catalogued. 
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With this unprecedented detail in resolving genetic mutations in cancer, it is increasingly clear 
that key drivers are still few within a tumor, at least those involved in gene coding regions, though 
the variety of possible drivers may be large between tumor types.  Based on age and incidence 
statistics, it is estimated that common adenocarcinomas, including breast, colon, and prostate, 
require 5-7 rate limiting events, while hematological malignancies may require fewer changes 
(Stratton et al., 2009).  Indeed, knowledge of oncogene and tumor suppressive functions has 
made it possible to rationally generate tumors with a minimal set of defined oncogenes in human 
cells (Hahn et al., 1999; Hahn and Weinberg, 2002).  Concordantly, recent mutational analysis of 
gliomas suggests that three critical signaling pathways are typically altered in brain cancers, 
including receptor tyrosine kinases (RTKs) and the p53 and Rb tumor suppressor pathways 
(Network, 2008).  With the implication that relatively few pathways are deregulated in each cancer 
type, and hence dependence on these limited pathways for the maintenance of tumor 
phenotypes, it seems that targeting one or a few of these pathways would be an effective way to 
kill cancers. 
 
1.2 Addiction to oncogene signaling pathways in cancer 
 
Persistent oncogenic signaling is required for maintenance of tumor phenotypes 
The initial discovery of oncogenes spurred a wave of continued discovery of important factors 
involved in the initiation of tumorigenesis.  The prescient words of J. Michael Bishop indicated 
that 
 
…cellular oncogenes are involved in tumorigenesis, whatever its proximal cause.  
Some of these genes may serve to initiate the genesis of tumors, some to 
sustain the final neoplastic phenotype, some may serve either purpose in 
different contexts.  Cellular oncogenes appear not to be tumorigenic in their 
native state; they must either be activated to abnormal levels of expression, or 
mutated so as to change some aspect of their function (Bishop, 1983). 
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At the time it had not been demonstrated that propagation of the tumor required persistent 
oncogenic signaling.  Since then, however, it has been demonstrated that in various contexts, 
cancers depend on the continued function of apical oncogenes—a phenomenon termed 
“oncogene addiction” (Weinstein, 2002).  The earliest evidence of oncogene addiction involved 
the targeted inhibition of the ERBB2 receptor tyrosine kinase in breast cancer.  Antisense 
oligonucleotide-mediated down-regulation of ERBB2 inhibited proliferation in breast cancer cell 
lines that had amplified ERBB2, but not in cell lines that lacked this amplification (Colomer et al., 
1994).  Subsequent studies in pancreatic cancer cell lines demonstrated the dependence of the 
tumor upon mutated KRAS, while cancer cells that did not have KRAS mutations were insensitive 
to KRAS depletion (Aoki et al., 1997).  These in vitro studies suggested that the specific 
sensitivity of tumors to the loss of mutant or amplified oncogenes reflected a dependence on the 
evolutionary history of the tumor—that the tumor was still dependent on the oncogene that drove 
its genesis. 
 
Murine models were generated to demonstrate this phenomenon in vivo.  MYC activation in the 
skin caused features of cancer, including hyperplasia, dysplasia, and angiogenesis, resulting in a 
papillomatosis at around three weeks post-induction.  Cessation of MYC induction, however, 
caused full regression of skin lesions (Pelengaris et al., 1999).  A similar phenotype was 
observed in p16INK4A-/- mice with activated RAS expression in the skin.  Melanomas developed 
after a period of RAS induction but depended on continued expression to maintain the tumor, as 
withdrawal from RASG12V caused these tumors to regress (Chin et al., 1999).  Similarly, 
withdrawal of MYC in MYC-driven T-cell leukemia caused regression of the tumor with evidence 
of differentiation, growth arrest, and apoptosis (Felsher and Bishop, 1999). 
 
The observed dependence of tumors to these oncogenes in vivo spurred the search for means of 
pharmacological inactivation of apical oncogenes, resulting in the development of inhibitors for 
multiple oncogenes, including HER2 (trastuzumab), BCR/ABL (imantinib), EGFR (gefitinib and 
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erlotinib), and VEGFR (sunitinib and sorafenib).  These drugs represented a paradigm shift in 
cancer therapy, and hence cancer susceptibility to oncogene inactivation was dubbed the 
“Achilles heel” of cancer  (Weinstein, 2002).  Despite the successes of these therapies, none of 
these drugs represent a cure for the cancers that they treat.  Because of the additional selection 
pressure from treatment, clones resistant to treatment emerge, whether it is by mutation of the 
targeted kinase (for example, drug resistance mutations that are frequently observed in BCR/ABL 
and EGFR in relapsed tumors), or whether tumor suppressive pathways, like p53, are inactivated, 
or whether the oncogene addiction shifts its burden to alternative oncogenes (Weinstein and Joe, 
2008).  Indeed, in a model of MYC-driven breast tumorigenesis, inactivation of MYC caused 
regression of tumors; however, tumors relapsed often bearing KRAS2 mutations, which are 
known to cooperate with MYC in tumorigenesis (Boxer et al., 2004).  Similarly, in human tumors 
engineered from 293 kidney epithelial cells, RAS-induction caused rapid tumor formation that was 
reversible upon de-induction of RAS; however, tumor maintenance could be enforced by the 
activation of the PI3K pathway in the absence of RAS (Lim and Counter, 2005).  These studies 
suggest that initiation of oncogenesis likely causes a rewiring of cellular circuitry that, even in the 
single oncogene MYC-driven tumors, retains many pre-malignant changes, making subsequent 
oncogenesis easily achievable.  The plasticity of these pathways indicates that we must find 
alternative modalities to successfully eradicate cancers. 
 
Latent tumor suppressor networks remain functional 
One of these modalities relies, like oncogene addiction, on exploiting the evolutionary history of 
the tumor.  In many tumors, inactivation of the tumor suppressors like p53 are critical to 
tumorigenesis since p53 responds to oncogenic stress by causing cell cycle arrest, differentiation, 
apoptosis, and senescence (Vousden and Lu, 2002).  Roughly 50% of tumors inactivate p53 by 
mutation, thus compromising its tumor suppressive ability; however, whether the tumor 
suppressive effector pathways of p53 remain intact was not known until relatively recent reports 
demonstrating the effects of p53-restoration in vivo.  Activation of p53 in Eμ-MYC driven lymphoid 
tumors caused widespread apoptosis of lymphoma cells (Martins et al., 2006).  Similarly, 
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autochthonous lymphomas—those spontaneously arising from p53-null mice—and sarcomas are 
sensitive to p53 re-introduction.  Though lymphomas typically responded by initiating cell death, 
sarcomas underwent senescence, reflecting an underlying difference in the molecular circuitry 
between the different cancer types (Ventura et al., 2007).  A third report also demonstrated a 
primarily senescence-mediated tumor suppression for transplanted RASG12V-induced liver tumors 
upon p53 reactivation (Xue et al., 2007). 
 
Together, these studies suggest that though p53 is inactivated in the course of tumorigenesis, the 
simple re-introduction of p53 expression is enough to drive its tumor suppressive functions.  This 
suggests that both the oncogenic signaling that drives p53 as well as the downstream effector 
mechanisms are largely intact and that re-activation of suppressed tumor suppressive programs 
is a tractable anti-cancer strategy. 
 
Taspase1 regulates the expression of oncogenes and tumor suppressors 
The clinical success of oncogene-inactivating therapies validates the biological concept of 
oncogene addiction, while re-introduction of tumor suppressors is a promising new avenue for the 
development of novel therapies.  Indeed, antagonists of MDM2, an E3-ligase responsible for p53 
degradation, have shown pre-clinical promise (Vassilev et al., 2004).  Both oncogene addiction 
and tumor suppressor sensitivity are important therapeutic concepts, and at the outset of this 
present work, we established that Taspase1 regulates the expression of core cell cycle 
components Cyclin E as well as p16INK4A, which are oncogenes and tumor suppressors, 
respectively (Takeda et al., 2006b).  This uniquely places Taspase1 at the hub of both pathways.  
Whether Taspase1, is required for maintenance of tumors, and hence, whether Taspase1 could 
serve as a pharmacological target for cancer therapy, is the question we will address with this 
work.   
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1.3 Taspase1 is an evolutionarily conserved threonine protease required for proper 
embryonic development and execution of the cell cycle 
 
The protease Taspase1 (threonine aspartase 1) is a threonine nucleophile endopeptidase 
composed nearly in its entirety of an asparaginase type II homology domain (Pfam PF01112).  
This family of enzymes includes L-asparaginase, which converts L-asparagine to L-aspartate by 
hydrolysis of the side chain amide bond.  Interestingly, Taspase1 participates in proteolysis of the 
peptide bond following specific aspartate residues with the consensus peptide sequence 
QXD/GXDD, thereby initiating a new class of proteases harboring the asparaginase type II 
homology domain.  Taspase1 is translated as a 420 amino acid, 50kDa proenzyme which 
undergoes auto-proteolytic maturation to generate 28kDa and 22kDa α and β subunits, 
respectively which form stable dimers and finally heterotetramers with enzymatic activity from the 
β-subunit N-terminal threonine nucleophile. 
 
Taspase1 was purified as the enzyme responsible for processing the protein product of the 
human homologue of Drosophila trithorax, the mixed lineage leukemia (MLL) transcriptional 
regulator, which is proteolyzed at two distinct sites, generating 320kDa N-terminal and 180kDa C-
terminal fragments.  Proteolyzed MLL fragments form stable heterodimers which localize to the 
nucleus where MLL complexes maintain proper Hox gene expression (Hsieh et al., 2003a; Hsieh 
et al., 2003b; Yokoyama et al., 2002).  MLL functionally antagonizes polycomb group proteins at 
Hox loci in order to properly define segmental identity.  Though MLL is not known to have 
sequence-specific DNA binding capacity, it is able to associate with other transcription factors 
and regulate chromatin structure through histone methylation via its C-terminal SET domain as 
well as with other epigenetic marks, whether by intrinsic ability or by virtue of cooperation with co-
activators or repressors (Milne et al., 2002).  Targeted disruption of a single MLL allele in mice 
results in overt loss of segmental identity with bi-directional homeotic transformations, while bi-
allelic loss results in mid-gestational embryonic lethality (Yu et al., 1995). 
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MLL is deregulated in blood cancers 
Aside from its role in development, MLL is involved in at least 60 different in-frame translocations 
at chromosome 11, between its N-terminal 1400 amino acids and various translocation partners.  
These translocations typify certain hematological malignancies, particularly infant leukemias and 
leukemias secondary to treatment with DNA-damaging chemotherapies such as topoisomerase II 
inhibitors.  It is estimated that up to 10% of blood disorders, including acute myeloid leukemia 
(AML), acute lymphocytic leukemia (ALL), biphenotypic leukemias, and myelodysplastic 
syndromes (MDS) harbor rearrangements of the MLL genomic locus, 11q23 (Dimartino and 
Cleary, 1999).  The mechanism by which MLL rearrangements cause leukemia is a matter for 
debate, though it has been suggested that leukemogenesis depends on effector functions of the 
reciprocal translocation partner, which remain largely uncharacterized (Ayton and Cleary, 2001). 
 
A common feature, however, between various MLL translocations is the retention of the first 1400 
amino acids of MLL.  Whether the oncogenic properties are due to MLL effector function, fusion 
partner gain of function, or haploinsufficiency of the translocation partner is unclear; however, in 
many fusions, the leukemogenic potential of MLL translocations depends on intact transactivation 
ability of the fusion protein.  Surprisingly, an MLL-β-galactosidase fusion knock in promotes 
leukemic transformation, which complicates understanding the underlying mechanism as it 
deemphasizes the effector function of the fusion partner (Dobson et al., 2000). 
 
Besides MLL translocations, two other forms of leukemogenic MLL alterations exist—partial 
tandem duplication (PTD) of MLL exons and PHD1 domain deletions in exon 8.  Given that 
leukemias bearing these mutations form in the absence of MLL translocations suggests that 
alteration of MLL function is ultimately responsible for leukemogenesis (Ayton and Cleary, 2001), 
though other evidence suggests that translocation partners require the intact function of both MLL 
as well as the translocation partner (Slany et al., 1998). 
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Evidence from our lab indicates that stabilization of MLL in fusion proteins usurps a cell cycle-
dependent, biphasic expression pattern of MLL seen in normal cells.  MLL accumulates in G1/S 
and G2/M cell cycle phase boundaries and are tagged for proteasomal degradation in S-phase 
and mitosis by SCFSKP2 and APCCDC20, respectively.  Loss of this biphasic expression results in a 
G1/S phase block in the case of MLL deficiency, or an intra-S-phase block in MLL over-
expression.  Surprisingly, MLL leukemic fusions resulted in persistent, moderate expression of 
MLL and consequent deregulation of cell cycle checkpoints (Liu et al., 2007).  This suggests that 
part of a unifying mechanism for MLL fusion-mediated leukemogenesis is the evasion of cell cycle 
checkpoints normally elicited by MLL deregulation. 
 
Despite the importance of MLL in certain leukemias, Taspase1 regulated MLL cleavage may not 
have an important role in regulating the MLL fusion protein in leukemogenesis per se, since 
leukemic fusions do not retain the Taspase1 consensus cleavage site.  However, Taspase1 may 
be of importance in MLL-fusion leukemias as a more general regulator of MLL function, 
particularly in cell cycle, as well as a regulator for functions subordinate to its other substrates. 
 
Loss of Taspase1 disrupts MLL function in development and the cell cycle 
Taspase1 knockout mice exhibit homeotic transformations consistent with abberant segmental 
identification due to alteration of MLL function, including a broadened anterior arch of the atlas, 
posterior transformation of C7 cervical vertebra to T1, anterior transformation from T8 to T7, 
among others (Takeda et al., 2006b).  MLL non-cleavage results in hypomorphic histone H3 
lysine 4 (H3K4) histone methyltransferase activity, which negatively affects its transactivation 
capability.  Additionally, non-cleavage of MLL may affect its target loci specificity as well as its 
ability to complex with key transcriptional co-regulators.  Either of these mechanisms could be in 
operation in regulating HOX gene expression, as Taspase1 si-RNA mediated knockdown 
prevents the maintenance of the 3’ HOXA group gene expression (Hsieh et al., 2003a).  
Importantly, though we illustrated the role of MLL proteolysis in developmental patterning, we 
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uncovered a distinct and important role for MLL proteolysis in regulation of the cell division cycle, 
specifically by regulating E2F-mediated Cyclin expression (Takeda et al., 2006b). 
 
Taspase1 knockout mice in the mixed B6/129 background are typically postnatal lethal, but the 
rare survivors exhibit small body size and male infertility reminiscent of Cyclin D1 and Cyclin E 
knockout mice (Geng et al., 2003; Sicinski et al., 1995).  Orderly progression though the cell cycle 
requires the concerted expression of Cyclins D, E, A, and B, which can be inhibited at various 
points by upstream Cyclin-dependent kinase inhibitors (CDKIs) p16INK4A, p21CIP1, p27KIP1, and 
others (Figure 1).  Taspase1-deficient murine embryonic fibroblasts (MEFs) exhibit delayed cell 
cycle entry as well as blunted expression of Cyclins E, A, and B.  We demonstrated that 
decreased transactivation of Cyclin E was associated with decreased H3K4 methylation at its 
promoter, suggesting that the hypomorphic H3K4 methyltrasferase activity from non-cleaved MLL 
might directly regulate Cyclin expression.  We found that E2F family members, which are the 
known transcriptional regulators of Cyclin expression, interact with MLL, suggesting that E2F 
family transcription factors direct MLL to Cyclin promoters to promote their full expression.  
Taspase1 deficient MEFs also exhibited increased p16INK4A expression, further compounding a 
cell cycle defect, as p16INK4A sh-RNA knockdown could rescue, to some extent, the Taspase1-null 
proliferative defect (Takeda et al., 2006b). 
 
The contributions of other Taspase1 substrates 
To dissect the contribution of MLL non-cleavage to the Taspase1-null phenotype, knock-in mice 
bearing non-cleavable alleles (nc) of MLL1 and MLL2 were generated.  MEFs from 
MLL1nc/nc;MLL2nc/nc embryos exhibited a milder proliferative defect than Taspase1-/- MEFs, 
suggesting that non-cleavage of other Taspase1 substrates may contribute to this defect. 
 
The α/β subunit of general transcription factor TFIIA was shown to be proteolytically processed at 
a QVDG motif, though it was originally thought to be cleaved N-terminal to an aspartate residue a 
few positions downstream.  It was later discovered that the protease responsible for cleavage 
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after the P1 aspartate was Taspase1 (Hoiby et al., 2004; Zhou et al., 2006).  Similarly, a paralog 
of TFIIA, ALF, which is specifically expressed in the testis, is also proteolyzed at a site consistent 
with a consensus site for Taspase1 cleavage (Figure 4.1).  Though the cleaved form of TFIIA is 
the predominant form in cells, the biological significance of this cleavage is still unclear.  TFIIA 
has been shown to interact with TATA binding protein (TBP) and stabilize its interaction with DNA 
at core promoters, yet it is also known to e critical for basal and activated transcription at TATA-
less promoters, suggesting a function beyond binding TBP (Hoiby et al., 2007). 
 
Cleaved TFIIAαβ is primed for ubiquitination and subsequent proteasomal degradation; yet, non-
cleavage did not affect TFIIA interaction with TFIIAγ or its ability to associate with TBP or its 
ability to handle bulk transcription (Zhou et al., 2006).  It has been postulated that cleavage helps 
to fine-tune expression levels of TFIIA, and it may be that the interactions between cleaved and 
un-cleaved forms of ALF and TFIIA with their respective cofactors increases the combinatorial 
diversity of their target promoter specificity or effector functions (Hoiby et al., 2007). 
 
Taspase1 as a cancer therapeutic target 
Taspase1 is highly expressed in nearly all tested cancer cell lines from various histological origins 
(Takeda et al., 2006b); moreover, Taspase1 is up-regulated in transformed clones MEFs selected 
through soft agar, including those initially transformed by E1A/RASG12V, MYC/RASG12V, and 
dominant negative p53 (DNP53)/RASG12V (Figure 4.3).  Loss of Taspase1 renders MEFs resistant 
to transformation by the same oncogene pairs and causes a profound depression in proliferation 
rate in unadulterated MEFs compared to those that are Taspase1 wild type.  Importantly, loss of 
Taspase1 results in the up-regulation of p16Ink4a with accordant hypo-phosphorylation of pRb and 
down-regulation of Cyclins E, A, and B.  Though the MLL-Cyclin axis is an important arm of 
Taspase1-orchestrated proliferation program, Cyclin D isoforms are largely unaffected by 
Taspase1 loss.  This may not be altogether surprising since Cyclin D levels are tightly controlled, 
with a halflife of 25 minutes and critical sensitivity to extracellular signals, in a manner different 
from Cyclins E, A, and B (Sherr and Roberts, 1995) (Figure 1A) .  As p16INK4A can both hinder the 
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assembly of the regulatory Cyclin D subunit and its catalytic kinase counterparts CDK4 and CDK6 
as well as inhibit CyclinD-CDK4/6 holoenzyme activity, the absence of Taspase1 may functionally 
inactivate Cyclin D by the de-repression (or the up-regulation) of p16INK4A.  
 
Though it is apparent that Taspase1 is critical to orchestrating normal cell cycle progression there 
is little known about the phenotypic output of Taspase1 deregulation in a disease context.  We 
hypothesize that the severe, compound cell cycle defect created by Taspase1 loss strongly 
argues that Taspase1 is a good candidate for targeted molecular inactivation as an effective 
cancer therapy.  The aim of this work will be address whether Taspase1 is critical to 
tumorigenesis and whether it subsequently bears responsibility for maintenance of established 
tumors.  Answering these questions will be the first step in establishing Taspase1 as a molecular 
target for cancer therapy.  
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Figure 1.  Taspase1 regulates the cell cycle through proteolysis of its substrate MLL 
 
A, Orderly progression of the cell cycle requires Taspase1.  B, Taspase1 deficiency can de-
regulate the cell cycle.  Depiction of Cyclin levels is adapted from Figure 1 of Sherr, CJ, 1996. 
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2.1.  Introduction 
 
Cancer is a state of disease that evolves over years of accumulating genetic and epigenetic 
abnormalities that confer an enhanced capacity to proliferate and evade apoptosis, eventually 
compromising the host (Hanahan and Weinberg, 2000; Vogelstein and Kinzler, 2004).  Although 
cancers are the product of complex selection pressures, it has been shown that abrogation of 
certain apical oncogenes can effectively inhibit cancer cell growth and prolong patient survival–a 
phenomenon termed “oncogene addiction” (Weinstein and Joe, 2008).  In accordance with this 
concept, molecularly targeted drugs have been developed and successfully utilized in treating 
cancer patients, exemplified by the use of imatinib for chronic myelogenous leukemia, erlotinib for 
lung cancer, and sunitinib for kidney cancer (Zhang et al., 2009).  Despite these recent strides 
against cancer, most end-stage cancer patients still succumb to their diseases, highlighting the 
urgent need for novel anti-cancer therapeutic strategies. Recently, the “non-oncogene addiction” 
hypothesis was proposed based on the heavy reliance of cancer cells on certain non-oncogenes 
for their continuous growth and survival, which offers a new class of therapeutic targets that are 
not conventional oncogenes (Luo et al., 2009).  Thus far, well-characterized non-oncogene 
addiction factors include the 26S proteasome, HSF1 (Dai et al., 2007a), and IRF4 (Shaffer et al., 
2008), which handles the rapid protein turnover, mediates the stress response, and maintains 
expression of the MYC oncogene, respectively. The fact that the proteasome inhibitor bortezomib 
is effective against multiple myeloma in human patients substantiates this new anti-cancer 
therapeutic concept (Adams, 2004). 
 
Uncontrolled proliferation and increased resistance to apoptosis are two cardinal features of 
cancer, and consequently, inhibiting cancer cell division and enhancing cancer cell death 
constitute two effective anti-cancer therapeutic strategies (Hanahan and Weinberg, 2000; Lowe et 
al., 2004).  Cancer cell cycle is typified by constitutively activated Cyclin/CDK complexes, 
resulting from either over-expression of Cyclins or down-regulation of CDK inhibitors (CDKIs) that 
are oncogenes and tumor-suppressor genes, respectively (Besson et al., 2008; Sherr, 1996).  By 
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analogy, impaired apoptosis in cancer cells can result from either up-regulation of anti-apoptotic 
(such as BCL-2, BCL-XL, and MCL-1) or down-regulation of pro-apoptotic BCL-2 family proteins 
(such as BAX, BAK, BIM, and PUMA) (Danial and Korsmeyer, 2004).  Targeted anti-cancer drugs 
have been developed and are on clinical trials based on these frameworks, and hence continued 
elucidation of the molecular control of cancer cell proliferation and cell death should unveil new 
anti-cancer targets and offer novel treatment options.  
 
Taspase1 (threonine aspartase 1) encodes a highly conserved 50kD α-β proenzyme which 
undergoes intramolecular autoproteolysis, generating a mature α28/β22 heterodimeric protease 
that displays an overall α/β/β/α structure (Hsieh et al., 2003a; Khan et al., 2005).  Taspase1 is the 
only protease within the family of enzymes that possesses an asparaginase_2 (PF01112) 
homology domain, while other members, including L-asparaginase and glycosylasparaginase, 
participate in the metabolism of asparagine and the ordered breakdown of N-linked glycoproteins, 
respectively (Hsieh et al., 2003a).  Taspase1-mediated cleavage follows distinct aspartate 
residues of conserved QXD/GXDD motifs (Hsieh et al., 2003b), suggesting that Taspase1 
evolved from hydrolyzing asparagine and glycosylasparagine to cleaving polypeptides.  The 
cloning of Taspase1 founded a novel class of endopeptidases which utilizes the N-terminal 
threonine of mature β subunit to cleave protein substrates after P1 aspartate. Taspase1 was 
initially purified as the protease which cleaves MLL to regulate HOX gene expression (Hsieh et 
al., 2003a).  Subsequent studies identified additional Taspase1 substrates, including MLL2, 
TFIIAα-β, ALF (TFIIAτ), and Drosophila HCF (dHCF) (Capotosti et al., 2007; Takeda et al., 
2006b; Zhou et al., 2006).  Collectively, all of the known Taspase1 substrates are nuclear factors 
that control gene expression, suggesting that Taspase1 cleaves nuclear factors to orchestrate 
genetic programs.  
 
Our prior study of Taspase1-/- mice uncovered a critical role of Taspase1 in cell cycle control 
(Takeda et al., 2006b).  In the absence of Taspase1, cell cycle is disrupted with decreased 
expression of Cyclins, including E, A, and B, and increased expression of CDK inhibitors (CDKIs), 
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including p16, p21, and p27 (Takeda et al., 2006b).  Hence, Taspase1 may play a permissive role 
in tumorigenesis, which is supported by the demonstrated resistance of Taspase1-/- mouse 
embryonic fibroblasts (MEFs) to oncogenic transformation induced by MYC, RAS, DNp53, and 
E1A.  Although the absence of Taspase1 poses a profound roadblock in cancer initiation (Takeda 
et al., 2006b), whether Taspase1 is required for cancer maintenance remains unknown.  Here, 
we demonstrate that Taspase1 is required to maintain a full cancer phenotype and is over-
expressed in primary human cancer tissues.  Deficiency of Taspase1 in human cancer cells 
results in impaired proliferation and enhanced susceptibility to death stimuli.  Taspase1 is not a 
classical oncogene, yet it enables expression of cancer characteristics; thus, it is better classified 
as a “non-oncogene addiction” protease.  As proteases are ideal drug targets, small molecule 
inhibitors of Taspase1 may be developed for cancer therapy.   
 
2.2  Taspase1 is required for efficient tumor maintenance in vitro 
 
Our prior study demonstrated that Taspase1-/- primary MEFs are defective in proliferation and 
thus resistant to in vitro transformation induced by well-characterized oncogene pairs including 
MYC-RASG12V, DNp53-RASG12V, and E1A-RASG12V (Takeda et al., 2006b).  These data highlight a 
critical participation of Taspase1 in cancer initiation, whereas whether Taspase1 has any role in 
cancer maintenance remains unanswered.  To address this question, we employed a tamoxifen-
inducible cre-lox system that allows for a precisely controlled genomic deletion of the conditional 
“floxed” (f) Taspase1 allele.  Specifically, MYC-RAS-transformed Rosa26-creERT;Taspase1f/- 
(R26-creERT;T1f/-) and R26-creERT;T1+/- MEFs were treated with a 6-hour pulse of 500 nM 4-
hydroxytamoxifen (4-OHT), which efficiently activated creERT fusion to excise the conditional 
allele of Taspase1 (Figure 2.1A).  Deletion of Taspase1 in MYC-RAS transformed R26-
creERT;T1f/- MEFs resulted in a profound proliferation block and disruption of colony formation 
on soft agar (Figure 2.1 B and C), indicating the requirement of Taspase1 for the proliferation of 
transformed cells.  Of note, in agreement with the known toxicity of Cre recombinase in MEFs 
(Loonstra et al., 2001), the pulse activation of creERT in control, MYC-RAS transformed R26-
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creERT;T1+/-, MEFs generated minor phenotypes in both assays (Figure 2.1 B and C).  Taken 
together, our data support a permissive role of Taspase1 in cancer maintenance apart from 
cancer initiation.  
 
2.3  Taspase1 is not an oncogene 
 
To further define the role of Taspase1 in tumorigenesis, we asked whether Taspase1 functions as 
an oncogene.  To directly assess the oncogenic potential of Taspase1, we employed two different 
sets of in vitro transformation assays that are commonly utilized to characterize newly discovered 
oncogenes.  First, we stably introduced Taspase1 into NIH/3T3 cells by retrovirus-mediated gene 
transduction, and determined the ability of transduced NIH/3T3 cells to grow on soft agar.  
Taspase1-transduced NIH/3T3 cells were unable to produce discernible colonies on soft agar, 
whereas RASG12V, as a positive control, efficiently rendered anchorage-independent growth 
(Figure 2.2 A and Figure 2.7 A).  Second, we tested the ability of Taspase1 to work in concert 
with RASG12V, MYC, or E1A to transform primary MEFs.  Taspase1 was unable to complement 
respective oncogenes to induce colony growth on soft agar (Figure 2.2 B and Figure 2.7 B).  
Thus, Taspase1 appears not fit the criteria for a classical oncogene despite its requirement for 
cancer initiation and maintenance.  The fact that Taspase1 is not an oncogene and yet enables 
oncogenesis suggests that Taspase1 is better classified as a “non-oncogene addiction” protease.  
 
2.4  Taspase1 is required for inhibition of human cancer cell proliferation 
 
Given the requirement of Taspase1 in murine oncogenesis in vitro, we chose a wide variety of 
human cancer cell lines from the well-characterized NCI-60 panel to study the role of Taspase1 in 
human carcinogenesis.  Human melanoma (SK-MEL-2), glioblastoma (U251), colon (HT-29), 
ovary (OVCAR-3), lung (A549), prostate (PC3), and breast (MDA-MB-231) cancer cell lines, 
representing major tissue types of human solid cancers, were examined.  The expression of 
Taspase1 in these cell lines was determined (Figure 2.3 A).  Knockdown of Taspase1 in these 
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human cancer cell lines compromised their proliferative capacity but to a varying degree (Figure 
2.3 B).  Interestingly, cancer cell lines with higher Taspase1 levels appear to exhibit a more 
profound proliferation block upon knockdown of Taspase1 (Figure 2.3 B and Figure 2.8), lending 
support to the notion that Taspase1 is co-opted by oncogenes to enforce cancer characteristics.  
Increased Taspase1 expression in cancer cells likely reflects an inherently elevated dependence 
on Taspase1 for maintaining a full cancer phenotype.  The molecular basis underlying the 
proliferation defect induced by the deficiency in Taspase1 was further interrogated with a primary 
focus on the regulation of Cyclin E, A, and CDKIs–known downstream targets of Taspase1 in the 
cell cycle control (Takeda et al., 2006b). Analyses of p16, p21, p27, Cyclin E2, and Cyclin A in 
these cancer cell lines revealed that the induction of p27 is most correlative with the growth 
inhibition induced by the Taspase1 loss (Figure 2.3 C).  For example, PC-3 and MDA-MB-231 
cells exhibited minimal growth inhibition upon Taspase1 knockdown, and no induction of p27 was 
observed in these Taspase1-knockdown cancer cells.  Interestingly, p16 and p21 were induced in 
SK-MEL-2 and A549 cell lines, respectively though the role of p27 in inhibiting cancer cell cycle 
may dominate over p16 and p21 due to frequent deletions of the p16INK4A/p14ARF locus, 
frequent mutation of p53, the upstream activator of p21, and the extremely rare incidence of p27 
mutations in human cancers (Besson et al., 2008).  Taspase1 regulation of p27 happens on a 
transcriptional as well as post-translational level (Figure 2.10). 
 
Taspase1 activates the transcription of Cyclins through MLL proteolysis (Takeda et al., 2006b; 
Tyagi et al., 2007).  However, we did not observe a reduction of Cyclin E2 or A expression in 
these cancer cell lines, suggesting that the Taspase1-MLL axis in regulating Cyclins may have 
been disrupted during the development of these cancers.  Of note, analysis of known genetic 
mutations in oncogenes and tumor suppressors in these cancer cell lines did not identify a causal 
mutation explaining the Taspase1 dependence (Table 2.1), highlighting the potential, general 
application of Taspase1 inactivation to inhibit cancer cell growth.  
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2.5  Requirement for Taspase1 in anoikis resistance 
 
As Taspase1 plays a critical role in sustaining cancer cell proliferation, we investigated whether 
Taspase1 is also involved in modulating cancer cell death–another principal mechanism often 
deregulated in tumorigenesis.  Interestingly, Taspase1 deficiency resulted in a minor increase in 
spontaneous apoptosis in both SK-MEL-2 and U251—cells that express high levels of Taspase1 
(Figure 2.4 A).  The increase in spontaneous apoptosis due to Taspase1 deficiency suggests that 
Taspase1 governs a fundamental process in cellular survival and that deregulation of this 
process, in the absence of Taspase1, would sensitize these cell lines to further death stimuli.  
The initiation of cell death by detachment from its substrata is an important, physiological initiator 
of apoptosis, termed anoikis, and the cellular resistance to anoikis constitutes a primary 
determinant of metastatic potential.  Accordingly, we determined whether the loss of Taspase1 in 
U251 and SK-MEL-2 would affect anoikis sensitivity.  Taspase1 deficiency sensitized SK-MEL-2 
and U251 cells to anoikis, which was not evident in other tested human cancer cell lines except to 
a lesser degree in A549 lung cancer cells (Figure 2.4 B).  The degree to which Taspase1-
sustained proliferation and enhanced anoikis resistance contribute to tumorigenesis was further 
interrogated with soft agar assays.  The ability of cells to form colonies on soft agar is a stringent 
in vitro predictor of in vivo tumorigenicity as soft agar imitates tumor microenvironment and 
thereby simultaneously assesses cellular proliferation and anoikis resistance.  Indeed, Taspase1 
deficiency in SK-MEL-2 and U251 cancer cells resulted in reduced colonies on soft agar (Figure 
2.4 C).  Altogether, our data reveal a novel capacity of Taspase1 in regulating cell death in 
human cancers. 
 
2.6  Taspase1 deficiency results in decreased MCL-1 level and increased sensitivity to 
chemotherapeutic agents and ABT-737.  
 
Melanoma and glioblastoma multiforme (GBM) are two highly aggressive human cancers that 
portend dismal outcomes when presenting at advanced stages.  Their increased sensitivity to 
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death upon Taspase1 knockdown prompted us to investigate the mechanism by which Taspase1 
regulates apoptosis in these cancers.  The BCL-2 family constitutes the core apoptotic machinery 
which operates at the mitochondrion, controlling cytochorome c release and caspase activation 
(Danial and Korsmeyer, 2004).  The activator BH3-only molecules BID, BIM, and PUMA directly 
activate the apoptotic effectors BAX and BAK, whereas BCL-2, BCL-XL, and MCL-1 inhibit 
apoptosis by sequestering BH3s (Figure 2.11 A) (Cheng et al., 2001; Kim et al., 2006; Kim et al., 
2009; Letai et al., 2002; Wei et al., 2001).  Based on this framework, we examined the expression 
of core regulators of mitochondrial apoptosis in control- or Taspase1-knockdown SK-MEL-2 and 
U251 cells, which identified decreased MCL-1 as the common alteration (Figure 2.5 A). 
Therefore, Taspase1 may function to maintain the MCL-1 level and thus modulate the apoptotic 
threshold in GBM and melanoma (Figure 2.11 B).  To examine this hypothesis, we first knocked 
down MCL-1 to a comparable level as observed in Taspase1-knockdown cells.  When comparing 
the propensity of Taspase1- or MCL-1-knockdown cells to undergo anoikis or DNA damage-
induced apoptosis, we observed a comparably enhanced apoptotic sensitivity in both U251 and 
SK-MEL-2 cells (Figure 2.5 and Figure 2.12).  Notably, the Taspase1 deficiency-induced down-
regulation of MCL-1 is of potential clinical significance.  As ABT-737, a specific inhibitor of BCL-
2/BCL-XL, is ineffective at killing MCL-1 over-expressing cancer cells (Oltersdorf et al., 2005; 
Opferman, 2006; van Delft et al., 2006), inactivation of Taspase1 may offer an effective strategy 
to sensitize these resistant cancer cells to ABT-737-induced apoptosis.  Accordingly, we treated 
control- or Taspase1-knockdown U251 and SK-MEL-2 cells with ABT-737 and demonstrated 
increased apoptosis in Taspase1 deficient cancer cells (Figure 2.5 C and Figure 2.12 B).  In 
summary, deficiency of Taspase1 confers sensitivity to apoptosis in GBM and melanoma cancer 
cells through down-regulation of MCL-1, suggesting a potential therapeutic benefit from 
combining Taspase1 inhibitors with currently-used cytotoxic agents as well as ABT-737 for 
cancer treatment.  
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2.7  Taspase1 regulates the protein half-life of MCL-1. 
 
The MCL-1 protein level can be titrated through transcriptional, translational, and post-
translational mechanisms, which explains its unusual capacity among BCL-2 family members to 
rapidly respond to environmental cues for cell death control (Opferman, 2006).  As Taspase1 
functions mainly through processing nuclear factors and thus orchestrating transcription, we 
determined if Taspase1 directly regulates the transcription of MCL-1.  Interestingly, there was no 
decrease of the MCL-1 transcript level in Taspase1 deficient U251 and SK-MEL-2 cells (Figure 
2.5 D and Figure 2.12 C).  Rather, Taspase1 deficiency shortened the protein half-life of MCL-1 
from ~1 hour to ~20 minutes in U251 cells (Figure 2.5 E).  Furthermore, treatment with 
proteasome inhibitor MG132 prevented the degradation of MCL-1 in both control- and Taspase1-
knockdown U251 cells.  The resultant half-life of MCL-1 is comparable between control- and 
Taspase1-knockdown cells upon MG132 treatment, suggesting that Taspase1 sustains the MCL-
1 protein by enhancing its protein stability. 
 
The control of MCL-1 degradation is complex and context dependent, which at least involves the 
E3 ligase MULE, the GSK3β signaling, and the inactivator BH3 NOXA (Chen et al., 2005a; Ding 
et al., 2007; Maurer et al., 2006; Zhong et al., 2005).  To provide further mechanistic details 
regarding how Taspase1 controls the MCL-1 degradation, we determined the expression of 
MULE and did not detect an increased transcript level of MULE in Taspase1-knockdown cells 
(Figure 5F and Figure 2.12 C).  Nor did we detect a difference in transcript of another described 
E3-ubiquitin ligase known to regulate MCL-1, β-TRCP, or a stabilizing chaperone for MCL-1, 
TCTP (Figure 2.5 F) (Ding et al., 2007; Liu et al., 2005).  We investigated whether Taspase1 
disrupts GSK3β signaling thereby extending the MCL-1 half-life.  Inhibition of GSK3β by TZDZ-8 
in Taspase1 deficient cells did not result in increased MCL-1 protein (Figure 2.13).  We also 
determined the expression of NOXA and did not detect an induction of NOXA protein in 
Taspase1-deficient cells to account for the increased degradation of MCL-1 (Figure 2.5A).  Taken 
together, these data indicate that Taspase1 regulates the MCL-1 protein through a distinct 
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proteasome-dependent mechanism that appears not to involve the suppression of MULE 
expression, the inactivation of the GSK3β signaling, or the suppression of NOXA expression.  
Taspase1 appears to regulate MCL-1 by the recently-described de-ubiquitinase for MCL1, 
USP9X at the transcriptional level, resulting in decreased USP9X protein and increased MCL-1 
ubiquitination (Figure 2.5 F, G, H) (Schwickart et al., 2010). 
 
2.8 Taspase1 is over-expressed in primary human GBM and melanoma tissues and its 
deficiency disrupts tumor growth in a xenograft model. 
 
Our in vitro assays indicate that Taspase1 enables a full cancer phenotype by facilitating cancer 
cell cycle progression and suppressing cancer cell death.  To probe the in vivo requirement of 
Taspase1 in human cancer growth, we performed a tumor xenograft assay using 
immunocompromised NOD;scid;IL2Rγ-/- mice.  Importantly, loss of Taspase1 significantly 
inhibited the growth of U251 tumors in NOD;scid;IL2Rγ-/- mice due to a decreased proliferative 
index as assessed by Ki67 staining, and increased cell death (Figure 2.6 A, B, and C).  
Furthermore, treatment of mice bearing U251 xenografts with ABT-737 resulted in a marked 
increase in cell death in Taspase1-deficient tumors (Figure 2.6 C). 
 
Several lines of evidence suggest that Taspase1 is recruited by oncogenes to maintain cancer 
characteristics during tumorigenesis. First, our in vitro and in vivo studies indicate that Taspase1 
functions as a critical node in the oncogenic network that sustains proliferation and suppresses 
cell death.  Second, Taspase1 is highly expressed in most of the NCI-60 human cancer cell lines 
(Takeda et al., 2006b).  Third, there is a positive correlation between the level of Taspase1 
expression and the degree of disruption in cancer phenotypes upon its inactivation in examined 
human cancer cell lines.  Theoretically, Taspase1 may be highly-expressed in certain human 
cancers, and based on our data, its over-expression would indicate a favorable therapeutic 
outcome upon its inhibition. 
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To enable assessment of Taspase1 expression in primary tissues, we established an 
immunohistochemistry (IHC) assay using a newly raised anti-Taspase1 monoclonal antibody.  
We focused on GBM and melanoma as our cell line data suggested a central for Taspase1 in the 
maintenance of these cancers.  Remarkably, Taspase1 is abundantly expressed in primary 
human GBM tissues (n = 19), whereas no or weak staining of Taspase1 is observed in adjacent 
or control brain sections (n = 13) that mainly consist of astroglial cells–the same cellular origin of 
GBM (Figure 2.6B and Figure 2.15).  The specificity of Taspase1 staining was confirmed as no 
signal was detected when the anti-Taspase1 antibody was pre-incubated with the Taspase1 
immunogen (Figure 2.16).  Of note, a recent, independent gene expression profiling analysis 
demonstrated over-expression of Taspase1 in primary human GBM tissues (Scrideli et al., 2008).   
 
Additionally, Taspase1 is preferentially expressed in melanoma compared to melanocytic nevus 
(Figure 2.17).  Similar expression of Taspase1 between melanocytic nevus and adjacent 
keratinocytes serves as an internal reference for Taspase1 expression, since normal 
melanocytes cannot be histologically differentiated from malignant melanocytes in the same 
section.  To quantify the preferential expression of Taspase1 in melanoma, we compared the 
relative immunoflourescence signal between melanoma and keratinocytes versus that of nevus 
and keratinocytes, which confirmed a statistically significant over-expression of Taspase1 in 
melanomas (Figure 2.17).  In summary, IHC and IF assays established to assess the expression 
of Taspase1 in primary human tissues demonstrate the over-expression of Taspase1 in primary, 
human GBM and melanoma.  This suggests that Taspase1 may have an important role in the 
pathogenesis of these human cancers and that it may serve as a new therapeutic target for these 
currently intractable diseases.  
 
2.9  Discussion  
 
Taspase1 plays an essential role in regulating embryonic cell cycle, as evidenced by the smaller 
body size of Taspase1-/- mice (Takeda et al., 2006b).  Molecularly, Taspase1 functions to 
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activate transcription of Cyclin E, A and B, and to suppress that of CDKIs p16, p21 and p27 in 
primary MEFs for cellular proliferation.  In contrast, the role of Taspase1 in adult tissue 
homeostasis is less clear.  As Taspase1 coordinates the expression of Cyclins and—known 
oncogenes and tumor suppressors, respectively—inactivation of Taspase1 may offer a novel 
mechanism to inhibit cancer cell proliferation.  In agreement with this hypothesis, deficiency of 
Taspase1 in human cancer cells impedes proliferation.  In contrast to our prior observation that 
the loss of Taspase1 has no impact on the baseline cell death of primary MEFs which express 
low levels of Taspase1 (Takeda et al., 2006b), GBM and melanoma cancer cells that express 
high levels of Taspase1 exhibited increased sensitivity to death stimuli upon Taspase1 
inactivation. 
 
Mechanistically, Taspase1 deficiency in U251 and SK-MEL-2 cells resulted in an increased 
degradation of MCL-1 via USP9X regulation, accounting for the enhanced death phenotype.  
MCL-1 is unique among anti-apoptotic BCL-2 family members as it rapidly responds to external 
signals and can be regulated by transcriptional, translational, and post-translational mechanisms 
(Opferman, 2006).  Regulation of MCL-1 protein turnover is itself complex and implicates multiple 
pathways.  MULE/ARFBP-1 was the first described E3-ligase required for MCL1 degradation, 
though in MULE deficient cells, MCL-1 is still degraded upon initiation of apoptosis, suggesting 
the existence of additional mechanisms for MCL-1 degradation (Zhong et al., 2005).  For 
example, the PI3K/AKT pathway inhibits GSK3β-mediated phosphorylation of MCL-1 and thereby 
prevents β-TrCP-mediated ubiquitylation and proteasomal degradation of MCL-1 (Ding et al., 
2007; Maurer et al., 2006).  Additionally, MCL-1 protein stability can be regulated by direct 
protein-protein interactions, as its interaction with NOXA is known to modulate MCL-1 turnover, 
and TCTP can stabilize MCL-1 (Chen et al., 2005a; Liu et al., 2005). 
 
How Taspase1 regulates the transcription of USP9X a matter for future study.  Nevertheless, 
down-regulation of MCL-1 by Taspase1 knockdown in cancer cell lines has important implications 
in cancer therapy.  The small molecule inhibitor of BCL2/BCL-XL, ABT-737, is currently 
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undergoing clinical trials.  Although ABT-737 is quite potent in killing certain types of cancer cells, 
it is ineffective against MCL-1 over-expressing tumors due to its inability to inhibit MCL-1 
(Konopleva et al., 2006; Oltersdorf et al., 2005; van Delft et al., 2006).  Accordingly, Taspase1 
inhibitors may synergize with ABT-737 to induce apoptosis in human cancers. 
 
There has been a relatively recent shift in focus from non-specific, cytotoxic therapies to a 
targeted approach in cancer treatment, supported by the observation that tumor survival is 
dependent on the continued function of the initiating oncogene–a phenomenon known as 
“oncogene addiction” (Weinstein, 2002).  Moreover, re-introduction of defective tumor 
suppressors can engage intrinsic tumor suppression mechanisms to destroy cancer cells, 
suggesting that the intrinsic tumor suppression network present at the inception of tumorigenesis 
remains largely intact yet dormant (Lowe et al., 2004).  In the present study, we find that 
Taspase1 loss modulates proliferative and death signals through the regulation of the tumor 
suppressive CDKIs and the pro-survival MCL-1, respectively, suggesting that Taspase1 functions 
as a critical node that when lost, intact tumor suppressive mechanisms can dominate, slowing 
cancer cell proliferation and rendering increased cancer cell susceptibility to death stimuli.   
 
Despite its involvement in oncogenesis, when introduced with established oncogenes, Taspase1 
failed to enable the survival and growth of MEFs on soft agar.  Recent studies have identified 
cellular proteins required for tumorigenesis that are non-oncogenes, a phenomenon termed “non-
oncogene addiction” (Luo et al., 2009). Hence, Taspase1 is better categorized as a non-
oncogene addiction protease.  Factors first described in this paradigm include the master heat 
shock response regulator heat shock factor 1 (HSF1) as well as interferon regulatory factor 4 
(IRF4).  Both are transcription factors that are positioned to regulate broad cellular processes that 
are required for normal cellular homeostasis, but upon which tumors have increased 
dependence.  HSF1 not only relieves proteotoxic stress by regulating heat shock proteins, but 
also modulates signaling from other oncogenic pathways, including ERK, and also regulates 
protein translation as well as glucose metabolism (Dai et al., 2007a).  IRF4 similarly executes a 
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broad genetic program that is involved in normal B-lymphocyte activation, but also supports the 
oncogenic platform by its regulation of membrane biogenesis as well as metabolic control, cell 
cycle progression, cell death, and differentiation (Shaffer et al., 2008).  Although the concept of 
targeting non-oncogene addiction factors for cancer treatment is novel, this strategy has proven 
fruitful with the successful application of the proteasome inhibitor bortezomib in treating certain 
human cancers.   
 
Taspase1 is similarly positioned to regulate a broad array of biological functions, including 
development, cellular proliferation, and cell death, as all of the Taspase1 substrates described to 
date are broad-acting transcription regulators, including TFIIA and MLL.  Although Taspase1 
plays a critical role in embryonic development, acute deletion of Taspase1 in mice did not incur 
obvious organismal distress and changes in blood counts (data not shown), supporting a potential 
application of Taspase1 inhibitors in treating cancers.  Though the mechanisms whereby 
Taspase1 is co-opted to promote tumorigenesis remain to be examined, the increased 
requirement for Taspase1 in certain cancers represents a possibility for a therapeutic window in 
which Taspase1 inhibition can work in conjunction with other forms of targeted and non-targeted 
cancer treatments.  Taspase1, as a site-specific protease, allows for rational design of substrate 
mimetic inhibitors as well as expedient high-throughput screening for potential small molecule 
therapeutic leads (Lee et al., 2009).  Although targeting the non-oncogene addiction network for 
cancer therapeutics is in its rudimentary stage, the successful utilization of this novel strategy is 
likely to add effective chemotherapeutic agents to our current armamentarium for combating 
cancers.  
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2.10  Materials and Methods  
 
Mice and MEFs 
Straight and conditional knockout mice of Taspase1 have been described. Taspase1+/- mice were 
crossed with Rosa26-creERT mice to generate R26-creERT;T1+/- mice. R26-creERT;T1+/- mice were 
crossed with T1f/+ mice to generate E13.5 primary MEFs. Genotyping for the Taspase1 allele and 
the retroviral transduction of the oncogene pairs, MYC plus RASG12V into MEFs have been 
described (Takeda et al., 2006b). 
 
Plasmids 
Nucleotide 480 of the human Taspase1 cDNA was mutated from T to A to create a silent 
mutation that abolished the internal EcoRI site using the QuickChange system (Stratagene).  The 
Taspase1 was inserted into a murine stem cell virus (MSCV) vector as a BamHI-EcoRI fragment 
downstream of an internal ribosomal entry site (IRES).  Human c-MYC, HRASG12V and E1A from 
adenovirus V early region were PCR cloned upstream of the IRES site using BglII and XhoI to 
generate c-MYC-IRES-T1, RASG12V-IRES-T1, and E1A-IRES-T1.  Constructs for MYC-IRES-
RASG12V and E1A-IRES-RASG12V were described previously (Takeda et al., 2006b). Taspase1 
RNAi oligos were generated by Oligoengine (Seattle, Washington), annealed and inserted into 
the vector pSuperior according to the manufacturer’s protocol.  hTaspase1 was targeted using 
two independent target sequences (sh-T1 is 5’-GGAAAGCCAAGACTCACAT-3’ and sh-T1#2 is 
5’-GCAGTAGATCATGGAATAC-3’), while scrambled shRNA control was acquired from 
Oligoengine (5’-GCGCGCTTTGTAGGATTCG-3’).  The target sequence for MCL-1 is (5’- 
CCCATCTCAGAGCCATAAG -3’). 
 
Cell Culture, Virus Production, and Retroviral Transduction. 
All cancer cell lines were provided by the NCI Developmental Therapeutics Program (Bethesda, 
MD) and cultured according to the provided instructions. Amphotrophic retroviruses were 
generated by transfection of 293T cells with a helper-free packaging system as described (19).  
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Infections were carried out for 48 hours with an 8 μg/mL supplement of polybrene (Sigma, St. 
Louis, MO) and subsequently selected for stable integrants in puromycin-containing media.  
 
Soft Agar Assay  
Cancer cell lines were plated at 105 cells per 6 cm dish in 0.3% agar noble layered on top of a 
0.6% agar noble base.  Cells were fed every 3 days with media, and after 2-3 weeks, colonies 
>0.1mm from 5 low power fields per plate were scored.  Soft agar assays for primary MEFs were 
performed as previously described (Takeda et al., 2006b). 
 
Anoikis assay  
Cancer cell lines were detached from their adherent substrata by trypsinization and 105 cells were 
plated, in their normal media, per well into 6-well plates coated with 6 mg of Poly-HEMA (Sigma, 
St. Louis, MO) to prevent attachment to tissue culture plastic.  Non-adherent and loosely 
adherent cells were harvested after three days, trypsinized, and stained with Annexin V-Cy3 
(Biovision, Mountain View, CA) and subjected to flow cytometry analysis on a FACSCalibur 
cytometer (BD Biosciences, San Jose, CA) to determine viability.  Primary MEFs used were 
under 3 passages and were cultured in IMDM, supplemented with 20% fetal bovine serum, 2 mM 
L-glutamine, 1 mM MEM non-essential amino acids, 1 mM sodium pyruvate, 0.1 mM β-
mercaptoethanol, and 100 U/ml penicillin/streptomycin (Invitrogen).  Primary MEFs were plated at 
105 cells per well in 2 ml of normal culture media, except that the serum was reduced to 1%, on 
Poly-HEMA coated 6-well plates and harvested 24 hours after plating and analyzed for viability as 
described above. 
 
Cell cycle analysis 
Cancer cell lines with control- or Taspase1-knockdown were stained with propidium iodide and 
subjected cell cycle analysis as previously described (Liu et al., 2007).  
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Quantitative RT-PCR and Protein Degradation Assay 
RNA was harvested from U251 and SK-MEL-2 cell lines using Trizol and first strand synthesis 
was performed using Superscript II (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
protocols.  Quantitative PCR was performed using SybrGreen PCR with an ABI 7300 Real Time 
PCR system.  Primers sequences used are as follows: 
 
HGNC symbol  Sequence 
BTRC (β-TrCP) 5’ CAGGATCATCGGATTCCACGGTCAG 3’ TCTACAACATTGACAGCAGCTCGGTG 
MCL1 5’ GCTGCATCGAACCATTAGCAGAAAG 3’ TTGGAGTCCAACTGCATAAACTGGT 
HUWE1 (MULE) 5’ CGGCATCTGTACAGTTCCATAGAGC 3’ AATGTTGTAGCCGAGTTAGCAGCG 
USP9X 5’ CCACCTCAAACCAAGGATCAATGAAATG 3’ CTCTCCACTCCATGTTGATTAGGAATAG 
ACTB 5’ CCTGGACTTCGAGCAAGAGATGG 3’ GATCTTCATTGTGCTGGGTGCCAG 
TPT1 (TCTP) 5’ CGAAAGCACAGTAATCACTGGTGTCG 3’ GATGTGCTTGATTTGTTCTGCAGCC 
CDKN1B (p27) 5’ GCTAACTCTGAGGACACGCATTTGG 3’ TTTGACGTCTTCTGAGGCCAGG 
 
Protein degradation assays were performed as previously described (Liu et al., 2007). 
 
Antibodies 
The polyclonal antibody used to detect Taspase1 was described (Takeda et al., 2006b). Other 
antibodies used include BID (Kim et al., 2006), BIM (N22-40, Calbiochem), PUMA (P4743, 
Sigma), NOXA (ab13654, AbCam), p21 (sc-397, Santa Cruz), p27 (sc-528, Santa Cruz), p16 
(G175-1239, BD Pharmingen), Cyclin E2 (4132, Cell Signaling), Cyclin A (C4170, Sigma), MCL-1 
(sc-819, Santa Cruz), BCL-2 (6C8, BD Pharmingen), BCL-XL (2762, Cell Signaling), Ubiquitin 
(FL-76 Santa Cruz), and USP9X (1C4, Novus Biologicals). Antibodies used specifically for murine 
antigens include p16 (sc-1207, Santa Cruz) and Mcl-1 (Rockland). A monoclonal antibody 
(10H2F6) that specifically recognizes the β22 subunit of human Taspase1 was generated 
(Promab), which was utilized for the IHC and IF assays. 
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Immunoblot Analysis 
Cellular lysates were collected in RIPA buffer (150 mM NaCl, 50 mM Tris-Cl, 0.1% SDS, 0.5% 
Na-deoxycholate, 1% NP-40) supplemented with Complete protease inhibitor cocktail (Roche) 
and separated using 10% or 12% Bis-Tris  
NuPAGE gels (Invitrogen, Carlsbad, CA).  Western blot images were acquired using the Fujifilm 
LAS-3000 system and quantified using ImageQuant software as described (Kim et al., 2006). 
 
Immunoprecipitation of MCL-1 
U251 control- and Taspase1-knockdown cell lines were lysed in EBC lysis buffer (120mM NaCl, 
50mM Tris-Cl, pH 8, 0.5% NP-40) supplemented with Complete protease inhibitor cocktail 
(Roche) and 20mM N-ethylmaleimide.  Lysates were incubated overnight at 4°C with 5µg MCL-1 
antibody (SC-819, Santa Cruz) adsorbed to protein-A beads (GE Healthcare).  Input and 
immunoprecipitated lysates were resolved on NuPAGE gels as described and blotted for MCL-1 
and ubiquitin (FL-76, Santa Cruz). 
 
Immunohistochemistry and Immunofluorescence 
Paraffin-embedded primary human cancer tissue sections were obtained from the Department of 
Pathology and Immunology at Washington University in Saint Louis and antigen retrieval was 
performed using a pressure cooker (Biocare) and Target Retrieval Solution (Dako). A monoclonal 
antibody (10H2F6) that specifically recognizes the β22 subunit of human Taspase1 was 
generated (Promab), which was utilized for the IHC and IF assays. For immunohistochemistry, 
glioblastoma, melanocytic nevi, and melanoma sections were stained with anti-Taspase1 
monoclonal antibody (10H2F6), while melanoma and melanocytic nevi were stained with Melan A 
(sc20032, Santa Cruz) to detect cells of melanocytic origin.  Sections were developed using the 
Vectastain Universal ABC Elite system (Vector Laboratories) and DAB+ chromogen (Dako) 
according to the manufacturer’s protocol.  Developed sections were counterstained with Mayer’s 
hematoxylin (Sigma). For immunofluorescence, sections were stained with anti-Taspase1 
monoclonal antibody (10H2F6) and an Alexa-488 conjugated goat-anti-mouse secondary 
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antibody (A11029, Invitrogen).  Slides were mounted and nuclei were counterstained with 
Slowfade+DAPI (Invitrogen). Indirect immunofluorescence images were acquired on an Olympus 
(IX51) microscope with Spot Cam.  Sections were quantitatively scored by capturing normal and 
tumor tissue in the same field of view, optimally, otherwise from the same section using identical 
capture settings.  Pixel signal intensity was measured on acquired images using ImageJ software 
(NIH).  For xenograft studies, freshly-isolated tumor xenografts were fixed in Bouin’s fixative, and 
7μm sections were subjected to antigen retrieval as stated above.  Assessment of proliferative 
index was performed by Ki-67 staining (MIB-1 clone, Dako USA), and developed using 
immunoperoxdase.  TUNEL staining was performed as per the manufacturer’s protocol (Roche). 
 
U251 glioblastoma lines transduced with control- or Taspase1-shRNA retroviruses were selected 
for 3 days in 1.5μg/mL puromycin.  Cells were then harvested and suspended in RPMI 1640 
media in a 2:1 ratio with growth factor reduced Matrigel (BD Biosciences, San Jose, CA).  Ten 
million cells were engrafted into each flank of male NOD-scid IL2Rγ-/- mice (Jackson Lab) 
between 6-8 weeks of age.  Tumor size was measured with calipers and volume determined as 
described previously (21). Tumor volumes were compared using a two-tailed Student’s t test. For 
in vivo ABT-737 treatment, mice were injected with vehicle (30% propylene glycol and 5% 
Tween-80 in D5W, pH 4.65) when tumors reached a volume of approximately 300-500mm3. 
Tumor Xenograft Assay 
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2.11 Figures 
 
 
 
 
 
Figure 2.1.  Taspase1 is required for the maintenance of MYC-RASG12V transformed mouse 
embryonic fibroblasts (MEFs). 
 
A, MYC-RASG12V transduced MEFs of the indicated genotypes were treated with 500 nM 4-
hydroxytamoxifen (4-OHT) for 6 hours to activate R26-creERT (a tamoxifen inducible Cre 
recombinase driven by the ubiquitous Rosa-26 promoter).  Deletion of the conditional (floxed; f) 
Taspase1 allele was confirmed by PCR at day 3.  B, 105 MYC-RASG12V transduced MEFs of the 
indicated genotypes were mock (DMSO) or 4-OHT treated for 6 hours before plating on 6 cm 
dishes. Cells were photographed and counted at day 5.  Data presented are mean ± SD of 
duplicates of three independent experiments.  C, 5x104 MYC-RASG12V transduced MEFs of the 
indicated genotypes were treated as in B and plated on soft agar.  Positive clones (≥200μm) were 
scored 1.5-2 weeks after the initial plating.  Insets are higher-magnification images.  Data 
presented are mean ± SD of duplicates of two independent experiments.  The average of colony 
number in mock treated plates was assigned a value of 1 for comparison.  Asterisk indicates p < 
0.01, determined by Fisher’s exact test.  
39 
 
 
 
 
 
 
 
 
Figure 2.2.  Taspase1 is not a classical oncogene. 
 
A, NIH/3T3 cells were transduced with the indicated genes and 5x104 cells were plated on soft 
agar in each 6 cm dish.  Positive clones (≥200μ m) were scored 10 days after the initial plating. 
Insets are higher-magnification images.  Data presented are mean ± SD of duplicates of two 
independent experiments.  T1 denotes Taspase1.  B, Wild-type primary MEFs were transduced 
with the indicated pairs of genes and 5x104 cells were plated on soft agar in each 6 cm dish.  
Positive clones (≥200μm) were scored 2-3 weeks after the initial plating.  Inserts are higher-
magnification images.  Data presented are mean ± SD of triplicates of two independent 
experiments.  
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Figure 2.3.  Taspase1 is required for the proliferation of human cancer cells. 
 
A, Taspase1 protein expression of the indicated human cancer cell lines was assessed by anti-
Taspase1 α28 antibody.  Western blot for β-actin indicates equal loading.  The relative 
expression of Taspase1 versus β-actin in hTERT-BJ-1 cells was assigned a value of 1 for 
comparison.  B, Human cancer cell lines with control- or Taspase1-knockdown were plated on 6-
well plates and cell number was assessed four days after initial plating.  The average cell number 
of control-shRNA cells was assigned a value of 1 for comparison.  Data presented are mean ± 
SD of duplicates of three independent experiments.  C, Stable knockdown of Taspase1 in the 
indicated human cancer cell lines was determined by anti-Taspase1 α28 immunoblot.  The 
expression of p16, p21, p27, Cyclin E2, and Cyclin A was determined by respective antibodies. 
The β-actin immunoblots indicate equal protein loading.   
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Figure 2.4.  Deficiency of Taspase1 results in increased anoikis and reversion of the transformed 
phenotype in SK-MEL-2 melanoma and U251 glioblastoma cells. 
 
A, Human cancer cell lines with control- or Taspase1-knockdown were stained with annexin V 
and analyzed by FACS to assess cell death.  B, Human cancer cell lines with control- or 
Taspase1-knockdown were cultured in PolyHEMA treated 6-well plates for 3 days, stained with 
annexin V, and analyzed by FACS to assess cell death.  C, SK-MEL-2 or U251 cells with control- 
or Taspase1-knockdown were plated on soft agar. Positive clones (≥100 μm) were scored 2-3 
weeks after the initial plating of 105 cells per 6 cm dish.  Annexin V stains positive for apoptotic 
cells.  Data presented in A, B, and C are mean ± SD duplicates of three independent 
experiments.  
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Figure 2.5.  Taspase1 deficiency de-stabilizes MCL-1 protein and sensitizes U251 glioblastoma 
cells to cell death stimuli. 
 
A, Cellular extracts of SK-MEL-2 or U251 cells with control- or Taspase1-knockdown were 
subjected to Western blot analyses using the indicated antibodies.  B, U251 cells with the 
indicated knockdown were treated with various apoptotic stimuli, stained with annexin V, and 
analyzed by FACS.  Cellular extracts of the indicated knockdown were subjected to immunoblot 
analyses using respective antibodies.  Anoikis assay cells were plated in PolyHEMA coated 
plates for 3 days.  For chemotherapy-induced cell death, cells were treated with 100 μg/mL of 
etoposide or 10 μM of doxorubicin for 30 hours.  Data presented are mean ± SD of duplicates of 
two independent experiments.  C, U251 cells with control- or Taspase1-knockdown were mock 
(DMSO) or ABT-737 treated for 24 hours, and cell death assessed by FACS analysis of annexin 
V staining.  Data presented are mean ± SD of triplicates of two independent experiments. D, 
Transcript levels of MCL-1 in control- or Taspase1-knockdown U251 cells were determined by 
quantitative RT-PCR analysis where the transcript level in control-knockdown cells was assigned 
a value of 1 for comparison.  E, U251 cells with control- or Taspase1-knockdown were subjected 
to cyclohexamide with or without MG132 treatment for the indicated periods of time, and protein 
levels of MCL-1 and β-actin were determined by immunoblot.  F, Analysis of transcript levels for 
known regulators of MCL-1 stability, including MULE, β-TrCP, TCTP, and USP9X.  G, U251 
treated with MG132 were lysed and immunoprecipitated for endogenous MCL-1.  Ubiquitin 
immunoblot determines MCL-1 ubiquitination state.  H, USP9X levels were determined for U251 
control- and Taspase1-knockdown by immunoblot. Thanks go to H. Liu for MCL-1 stability and 
ubiquitination westerns, and to S. Takeda for MCL-1 qPCR.  
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Figure 2.6.  Taspase1 is over-expressed in human glioblastoma and is required for for U251 
glioblastoma maintenance in vivo. 
 
A, U251 cells with control- or Taspase1-knockdown were injected into the flanks of NOD-scid 
IL2Rγ-/- mice and tumor growth was measured every other day. * indicates p < 0.001.  B, 
Proliferative index of U251 xenografts was determined by Ki-67 immunohistochemistry.  Sections 
shown at 20X magnification.  Bar graph represents mean ± SEM of Ki-67+ cells per 10X field (10 
fields per tumor, n=2 tumors each).  C, Cell death resulting from ABT-737 treatment was 
assessed by TUNEL assay 12h after a single IP injection of vehicle control or ABT-737.  Sections 
shown are 10X fields of FITC-TdT (green) and DAPI (blue).  Bar graph represents mean ± SEM 
of TUNEL+ cells per 10X fields (10 fields per tumor, n=2 tumors each).  D, Immunohistochemical 
analysis of Taspase1 expression in primary human GBM and adjacent normal brain using an anti-
Taspase1 monoclonal antibody (10H2F6).  High magnification pictures of boxed areas are 
provided where the left panel is normal and the right is tumor.  
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Figure 2.7.  Taspase1 over-expression in NIH/3T3 and primary MEFs. 
 
A, Western blot analysis of Taspase1 expression in NIH/3T3 cells transduced with vector control, 
RASG12V, and human Taspase1 (T1).  B, Western blot analysis of Taspase1 expression in 
primary MEFs transduced with vector control or Taspase1 in conjunction with the indicated 
oncogenes. 
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Figure 2.8.  Taspase1 loss using two, independent sh-RNAs impedes proliferation in SK-MEL-2 
and U251. 
 
A, Western blot analysis of Taspase1 level in U251 and SK-MEL-2 cell lines transduced with 
Taspase1 shRNA constructs.  B, Cells with the indicated knockdown were plated on 6 well plates 
and counted four days after the initial plating.  Data represents the proportion of cells compared 
to control knockdown where the average cell number of control knockdown cells was assigned a 
value of 1. Data presented are mean ± SD of duplicates of two independent experiments. 
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Figure 2.9.  Cell cycle analysis of human cancer cell lines with Taspase1 deficiency 
 
Cell cycle analyses of cancer cell lines with control- or Taspase1-knockdown by propidium iodide 
(PI) staining and FACS analysis for DNA content.  U251 cells were not included due to highly 
variable DNA content (Pershouse et al., 1993). 
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Figure 2.10.  Analysis of p27KIP1 regulation in U251 with Taspase1 deficiency. 
 
A, Transcript level of p27KIP1 was determined by qRT-PCR, where U251 control knockdown was 
assigned a value of 1. Asterisk indicates p < 0.05.  B, U251 cells with control- or Taspase1-
knockdown were treated with 10µg/mL cycloheximide for the indicated times and immunoblotted 
for p27KIP1.  Actin blot indicates equal loading. 
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Figure 2.11.  Models for the core apoptotic pathway and its interaction with Taspase1 
 
A, Model depicts the hierarchical regulation of apoptosis. B, Model for the loss of Taspase1 
expression in regulation of cell death in susceptible cancer cells. 
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Figure 2.12.  Analysis of SK-MEL-2 sensitivity to cell death with Taspase1 deficiency 
  
A, SK-MEL-2 melanoma cells with control-, Taspase1-, and MCL1-knockdown were analyzed for 
cell death by annexin V staining after being subjected to polyHEMA culture culture for 3 days, or 
200μg/mL etoposide or 10μM doxorubicin for 30 hours. Data presented are mean ± SD of 
duplicates of two independent experiments. B, SK-MEL-2 cells with control- or Taspase1-
knockdown were treated with DMSO (mock) or 500nM of ABT-737 for 24 hours and analyzed for 
cell death by annexin V staining.  Data presented are mean ± SD of triplicates of two independent 
experiments.  C, MCL-1 transcript level in SK-MEL-2 was determined by quantitative RT-PCR 
analysis. Data presented are mean ± SD of duplicates of two independent experiments. 
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Figure 2.13.  MCL-1 level is not stabilized by GSK3-β inhibition in Taspase1-deficient cells 
 
A, U251 cells with control- or Taspase1-knockdown were subjected to treatment with 4 µM TZDZ-
8, an inhibitor of GSK3β, for 12 hours, and protein levels were determined with the indicated 
antibodies.  B, U251 and MDA-MB-231 cells were treated with the indicated doses of TZDZ-8 for 
12 hours and the protein levels were determined with the indicated antibodies. MCL-1 was 
stabilized in MDA-MB-231 but not U251 cells upon the inhibition of GSK3-β. 
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Figure 2.14.  Taspase1 levels in U251 glioblastoma xenografts. 
 
Individual tumors expressing the indicated knockdown construct were harvested from xenografted 
NOD-scid;IL2Rγ-/- mice at day 24 post-injection.  Tumor lysates were prepared and subjected to 
immunoblot analyses with the indicated antibodies. 
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Figure 2.15.  Examination of Taspase1 expression in human glioblastoma 
 
Immunohistochemical analysis for Taspase1 expression in paired primary GBM and normal brain 
tissues from the same group of patients (n = 13) were scored and presented as a scatter plot. 
Sections were scored for the predominant (>50%) cell type based on the outlined criteria (left 
panel) and the statistical significance was determined by Chi-squared test.  Normal refers to 
histological normal white matter.  Small versus large nucleoli are defined by the diameter of 
individual nucleolus ≤ 25% or >25% compared to the diameter of its  respective nucleus. Asterisk 
denotes p < 0.0001. 
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Figure 2.16.  Demonstration of the specificity of Taspase1 immunohistochemistry. 
 
The specificity of immunohistochemical staining for Taspase1 expression in primary glioblastoma 
tissues by the anti-Taspase1 primary antibody (10H2F6) was demonstrated by the loss of 
staining when 50 μg/mL of the recombinant Taspase1 immunogen but not 50 μg/mL BSA (non-
specific control) was pre-incubated with the antibody before staining. 
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Figure 2.17.  Examination of Taspase1 expression in melanoma. 
 
A, Immunohistochemical analysis of Taspase1 expression in melanoma and melanocytic nevus 
was performed with an anti-Taspase1 monoclonal antibody (10H2F6) (right).  
Immunohistochemical stain of consecutive sections using an anti-Melan A antibody identify both 
benign and malignant melanocytes as a reference (left). B, Immunofluorescence analysis of 
Taspase1 expression on melanoma (left bottom panel) and melanocytic nevus (right bottom 
panel) was performed with an anti-Taspase1 monoclonal antibody (10H2F6), where dotted lines 
demarcate regions that are predominantly melanocytes from keratinocytes.  
Immunohistochemical stain of consecutive sections using an anti-Melan A antibody identify both 
benign and malignant melanocytes as a reference (top two panels). 
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Table 2.1.   Mutation status of sequenced genes in the NCI60 cancer cell lines used in this study. 
 
Known mutations in the cancer cell lines used in this study were retrieved from the Cancer 
Genome Project (http://www.sanger.ac.uk/genetics/CGP). 
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3.1 Taspase1 is an evolutionarily conserved threonine protease important in 
tumorigenesis and maintenance 
 
Taspase1 is an evolutionarily conserved N-terminal nucleophile protease 
Taspase1 is a threonine endopeptidase that is highly conserved from plants to fish, flies, and 
man.  Taspase1 is translated as a 50kDa proenzyme that is comprised almost entirely of an 
Asparaginase_2 domain (Pfam PF01112), which is part of a larger superfamily of proteins known 
as the N-terminal nucleophile (Ntn) hydrolases.  As the name suggests, reactive nucleophiles of 
this family reside on the N-terminus of mature Ntn hydrolases, which are typically translated as 
proenzymes that require autoproteolytic activation.  At the core of the Ntn hydrolase structure 
resides an αββα folding motif with α helices flanking anti-parallel β sheets, which is true of 
Taspase1 as well (Figure 3.1), though the crystal structure reveals significant conformational 
divergence from other Asparaginase_2 proteins (Khan et al., 2005). 
 
Other members of the Asparaginase_2 family include L-asparaginase, which catalyzes the de-
amidiation of asparagine to aspartic acid and aspartyl-glucosaminidase (AGA), which is involved 
in the breakdown of N-linked glycoproteins, thus making Taspase1 the only protease in this 
family.  Despite divergence in structural conformation and substrate specificity, autocatalytic 
activation is a common feature of Ntn hydrolases, where the active nucleophile in the mature 
enzyme is also thought to be the autocatalytic nucleophile (Saarela et al., 2004).  The maturation 
from Ntn pro-enzymes involves an initial N → O acyl rearrangement, which reveals the catalytic 
α-amino group on the threonine nucleophile.  In lysosomal AGA, like Taspase1, aspartic acid 
precedes the threonine nucleophile, and it is thought to provide conformational strain, promoting 
activation. 
 
Autoproteolysis of the Taspase1 pro-enzyme forms a mature α28/β22 heterodimeric enzyme 
which further assembles into the active heterotetrameric enzyme (Hsieh et al., 2003a; Khan et al., 
2005).  Taspase1-mediated cleavage follows distinct aspartate residues of conserved 
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QψD/GXXD motifs (Figure 3.1).  Taspase1 was cloned as the protease responsible for the 
proteolytic maturation of the human homolog of Drosophila trithorax, Mixed Lineage Leukemia 
(MLL).  Since its discovery, additional Taspase1 substrates were identified, including MLL2, 
TFIIAα-β (GTF2A1), ALF (TFIIAτ), and Drosophila HCF (dHCF), which are all nuclear factors, 
suggesting that Taspase1 potentially modulates a broad array of biological processes (Capotosti 
et al., 2007; Takeda et al., 2006b; Zhou et al., 2006).  Indeed Taspase1-mediated maturation of 
HCF and MLL is critical for orchestrating cell cycle progression (Julien and Herr, 2003; Takeda et 
al., 2006b). 
 
Taspase1 is required for tumor maintenance 
Our prior studies demonstrated that Taspase1 is required for efficient oncogenic transformation 
and is critical for maintenance of the transformed phenotype in genetically defined murine tumor 
cells.  Deficiency of Taspase1 decreased the proliferative capacity of a variety of human cancer 
cell lines, including melanoma, glioblastoma and adenocarcinoma of the colon, ovary, lung, 
prostate, and breast.  In certain cell lines, Taspase1 maintains the expression of the anti-
apoptotic BCL-2 family member MCL-1.  Loss of Taspase1 in the glioblastoma cell line U251 
increased its sensitivity to chemotherapies like doxorubin and etoposide, in vitro.  Mechanistically, 
we expected the decrease in MCL-1 level to increase the sensitivity to the selective BCL-2/BCL-
XL antagonist ABT-737.  Indeed, Taspase1 deficiency caused U251 glioblastoma to have a lower 
proliferative index, increased basal cell death, and increased sensitivity to ABT-737 treatment in 
vivo.  The anti-cancer effect of Taspase1 loss in cancer cell lines in vitro and in vivo, and that 
Taspase1 is over-expressed in human cancers, spurred the search for Taspase1 inhibitors to 
validate Taspase1 as a pharmacological target for cancer therapy (Niehof and Borlak, 2008; 
Scrideli et al., 2008; Takeda et al., 2006b). 
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3.2 Rational Design of peptidomimetic inhibitors of Taspase1 
 
Structural properties of Taspase1 guide rational design of peptide inhibitors 
Taspase1 has an exquisite specificity for its substrate cleavage site.  MLL harbors two Taspase1 
cleavage sites—cleavage site 1 and 2 (CS1 and CS2), which are separated by 53 amino acids, 
where CS2 is thought to be more efficiently processed than CS1 (Hsieh et al., 2003a).  Alanine 
scanning mutagenesis of the MLL CS2 (KISQLD/GVDD) reveals a low tolerance for substitutions 
in the cleavage site consensus.  Mutations revealed that the P1 aspartate and P1’ glycine are 
essential, while P2 leucine, P3 gluatmine, and P5 isoleucine are important but non-essential for 
Taspase1-mediated proteolysis, whereas aspartates at position P3’ and P4’ are dispensable 
(Chen, et al. in preparation).  With such specificity, rational design of a Taspase1 inhibitor might 
be possible, based on a short peptide specific to Taspase1 substrate MLL CS2. 
 
Methods for assessment of Taspase1 inhibition 
To assess potential inhibitors, we generated three assays and adapted them for validation of 
Taspase1 inhibition, screening for further inhibitors of Taspase1, or both.  The first was 
established while isolating Taspase1, employing an activity-based purification scheme which 
utilized an in vitro cleavage system to chase MLL-cleavage ability in cellular fractions (Hsieh et 
al., 2003a).  An in vitro transcribed and translated (IVTT), 35S methionine-labeled fragment of 
human MLL1 (aa2,500-2,800) with a mutation engineered at the CS1, was employed as a CS2-
specific cleavage reporter (p45MLL/CS2).  The cleavage of p45MLL/CS2 by recombinant Taspase1 
(rTaspase1) was resolved by SDS-PAGE and examined by autoradiography.  Inhibition of 
Taspase1 cleavage results in the disappearance of cleaved product p33 and an increase in the 
non-cleaved p45MLL/CS2 (Figure 3.2).  Though this method benefits from high specificity, it is not 
practical for use as a high-throughput screening method. 
 
The second assay is a cell-based assay developed as a method to assess the ability of potential 
Taspase1 inhibitors to penetrate the plasma membrane and inhibit Taspase1 mediated cleavage 
of a dual-fluorescent reporter substrate.  A 293T human embryonic kidney cell line was 
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engineered to stably express a dual fluorescent Taspase1 proteolytic reporter (DFPR).  The 
DFPR is constructed from a peptide similar to the in vitro cleavage assay described previously.  
The DFPR reporter consists of the MLL polypeptide (aa2,400-2,900, p75MLL), which contains the 
CS1 and CS2 Taspase1 cleavage sites and is flanked on the N-terminal by EGFP/NES (nuclear 
export signal) fusion and on the C-terminal by a NLS (nuclear localization signal)/dsRED2 fusion.  
Upon Taspase1-mediated cleavage, DFPR displays cytosolic green (eGFP/NES-p47) and 
nuclear red fluorescence (p28-NLS/dsRED2) that can be detected by fluorescence microscopy.  
Inhibition of Taspase1 results in non-cleavage of newly synthesized DFPR, exhibiting increased 
yellow fluorescence upon the merge of green and red fluorescence (Figure 3.3).  This method is 
suitable for microscopy based high throughput screening, and though the sensitivity and 
specificity of Taspase1 cleavage inhibition is less than that of the in vitro cleavage assay, this 
assay readily identifies compounds which are already bioactive. 
 
The final assay developed to assess Taspase1 inhibition is a FRET (Fluorescence Resonance 
Energy Transfer)-based in vitro cleavage assay. The FRET-based Taspase1 proteolytic reporter 
(FRPR, MCA-KISQLDGVDD-DNP) consists of a 10 amino acid MLL CS2 consensus sequence 
conjugated with a fluorogenic coumarin (MCA) group and a 2,4-dinitrophenyl (DNP) quenching 
group at its N- and C-terminus, respectively (Figure 3.4).  Cleavage of the FRPR substrate can be 
monitored over time using a spectrofluorometer, and the kinetics of inhibition can be determined 
by varying the inhibitor concentration and performing non-linear regression on the aggregated 
reaction progress curves.  In this regard, this FRET-based assay was validated by establishing 
that HTI-9 (ISQLAGVDD) which is an alanine mutant of the cleavage reporter acts as a 
competitive inhibitor of the FRPR cleavage reaction (Figure 3.5).  This assay has been adapted 
for both for determination of inhibition kinetics as well as a high throughput screen, where a dose-
responsive decrease in endpoint fluorescence is scored as positive for Taspase1 inhibitory 
activity. 
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Rational design of peptide-based Taspase1 inhibitors 
The only other characterized threonine nucleophile protease in the human genome is the 
proteasome, which, like Taspase1, is a member of the Ntn hydrolase superfamily.  The original 
proteasome inhibitors consisted of peptidyl aldehydes which inhibited the proteasome by forming 
a hemi-acetal adduct with the threonine nucleophile.  Based on subsequent studies revealing that 
leucine is the preferred P1 position for proteasomeal cleavage, a Phe-Leu dipeptidyl boronic acid 
was developed with specific sub-nanomolar inhibitory activity against the proteasome.  The 
boronic acid was postulated to form stable tetrahedral intermediates with the threonine 
nucleophile, while remaining much less reactive to cysteine proteases because of the weak 
bonding efficiency between sulfur and boron (Adams et al., 1998).  The dipeptidyl boronic acid, 
known now as Velcade (bortezomib), has single agent efficacy in treatment of multiple myeloma 
(MM) and non-Hodgkin’s lymphoma (NHL). 
 
Second generation peptide-based proteasome inhibitors have been generated with epoxyketone 
pharmacophores, which was a development based on the observation that a microbial anti-tumor 
natural product epoxomicin had inhibitory activity at the proteasome (Sin et al., 1999).  The potent 
and specific inhibition of the proteasome was structurally defined by its selective binding of the 
peptide sequence to the substrate binding site of the proteasome as well as the stereospecific 
and irreversible interaction of the epoxyketone with the reactive threonine nucleophile (Groll et al., 
2000).  Subsequent modification of a Phe-Leu-Phe-Leu tetrapetide epoxyketone generated the 
proteasome inhibitor carfilzomib, which is currently under clinical trial for MM (Demo et al., 2007; 
Elofsson et al., 1999). 
 
Based on the proteasome as a precedent for rational design of effective threonine protease 
inhibitors, we collaborated with M. Bogyo and colleagues at Stanford University to design, 
generate, and test short peptide inhibitors for Taspase1.  Additionally, the evolutionary history of 
Taspase1 informs the placement of reactive pharmacophores.  As a descendant of an 
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asparaginase, which cleaves the isopeptide bond on asparagines to generate aspartate, 
Taspase1 may have specificity for either main chain substrates, or isopeptide substitutions. 
 
Based on the MLL CS2, the ISQLD peptide was modified on the P1 aspartic acid residue to bear 
vinyl sulfone, vinyl ketone, epoxyketone, and boronic acid pharmacophores, which are known to 
be effective at inhibiting the proteasome threonine nucleophile (Figure 3.6) (Lee et al., 2009).  
Using the FRET-based kinetics assay, the vinyl sulfone substitution (yzm18) on the main 
backbone of the peptide inhibitor exhibited the most potent activity with an IC50 of 29μM, while the 
vinyl ketone (yzm19) was less potent with an IC50 of 63μM.  Interestingly, the vinyl sulfone placed 
on the P1 aspartate side chain was minimally active with an IC50 > 100μM, suggesting 
pharmacophores, at least the vinyl sulfone, placed on the main chain are likely to be more potent 
inhibitors of Taspase1 (Figure 3.6).  Continued incubation with yzm18 did not increase the 
potency of substrate cleavage inhibition, suggesting that yzm18 is not acting as a covalent, 
irreversible inhibitor of Taspase1 (Figure 3.7). 
 
Treatment of SV40-transformed murine embryonic fibroblasts (MEFs) with the ISQLD-vinyl 
sulfone had minimal ability to inhibit cellular proliferation, which is a phenotype expected from 
Taspase1 loss, based on our previous studies (Figure 3.8) (Takeda et al., 2006b).  Whether this 
is due to poor cell permeability, relatively weak ability to inhibit Taspase1, or both is a matter for 
further investigation.  Although the in vivo application of ISQLD-vinyl sulfone was limited, these 
inhibitors represent a proof of principal of rationally designed, peptide-based Taspase1 inhibitors 
and offers valuable mechanistic insights to aid the future development of more potent inhibitors. 
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3.3  A cell based dual-fluorescence reporter screen identifies TASPIN-1 as a potent 
inhibitor of Taspase1 in vitro and in vivo 
 
A cell-based screen to identify small molecule inhibitors of Taspase1 
To identify bioactive Taspase1 inhibitors, we employed a cell-based screen using a 293T cell line 
expressing a dual fluorescence Taspase1 substrate cleavage reporter where inhibition of 
Taspase1 results in the non-cleavage of the reporter and subsequent co-localization of red and 
green signals, as described in section 3.2.  We screened the National Cancer institute’s 
Developmental Therapeutics Program (NCI-DTP) diversity set library of 1,900 compounds and 
identified 50 candidate inhibitors.  A secondary screen using the in vitro cleavage assay was 
performed, which confirmed five compounds as highly active Taspase1 inhibitors (Figure 3.9).  To 
further characterize these inhibitors, a tertiary screen was undertaken in which we employed the 
well-characterized Caspase-8-mediated cleavage of the BH3-only molecule BID as a reporter 
system to assess the target promiscuity of identified inhibitors.  Caspases, like Taspase1, 
proteolyze substrates after the P1 aspartate of their target cleavage sequence (Zha et al., 2000) 
and thus can serve as a stringent control for the specificity of any observed inhibitory activity.  
Among the top five compounds exhibiting Taspase1 inhibitory activity, four have no specificity for 
Taspase1 over Caspase 8 inhibition, while one compound—NSC48300—only targets Taspase1 
(Figure 3.9).  This establishes NSC48300, [4-[(4-arsonophenyl)methyl]phenyl] arsonic acid, as a 
very specific small-molecule Taspase1 inhibitor and was thus designated as TASPIN-1. 
 
TASPIN-1 is a non-competitive and reversible inhibitor of Taspase1 
To characterize NSC48300/TASPIN-1 further, we employed the in vitro cleavage assay to 
determine whether TASPIN-1 is a more potent inhibitor than our previously described peptide 
vinyl sulfone (yzm18).  The IC50 for TASPIN-1 is less than 10μM (Figure 3.10 A), which is less 
than the IC50 of yzm18.  Like yzm18, it appears that TASPIN-1 is a reversible inhibitor of 
Taspase1 as increased time of incubation with Taspase1 does not increase the inhibition of 
substrate cleavage (Figure 3.10 B).  Interestingly, the overall structure of TASPIN-1, including its 
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hydrophobic, symmetric core specifies its inhibitory capability as free arsenic acid itself does not 
inhibit Taspase1, even at high concentrations (Figure 3.10 A).  In silico pharmacophore modeling 
based on TASPIN-1 predicted several possible inhibitors already in the NCI chemical repository 
by docking TASPIN-1 in the crystal structure for Taspase1 and assuming a tetrahedral Asp-Gly 
adduct as a model.  These structural probes, when tested, suggest that the arsenic acid moiety is 
still important for inhibitory activity, and that substitutions on the hydrophobic core of 
NSC48300/TASPIN-1 decrease the potency of inhibition (Figure 3.10). 
 
To characterize the mechanism by which NSC48300/TASPIN-1 inhibits Taspase1, we performed 
kinetic analyses using a FRET-based kinetics assay.  Taspase1 incubation with the quenched 
pair fluorescence probe MCA-KISQLDGVDD-DNP results in its cleavage and release of the DNP 
quencher and subsequent linear accumulation in fluorescent signal over time (Figure 3.5 and 
3.11).  This analysis determined an apparent KM of the FRPR as 9.20 ± 2.43 µM (Figure 3.11).  
Reaction progress was monitored with varying concentrations of TASPIN-1 and steady state 
rates were plotted against varying reporter substrate concentrations.  Non-linear regression was 
performed and fitting the model from equation 1 (see Methods and Materials) revealed that 
TASPIN-1 is a non-competitive inhibitor of Taspase1 with a KI of 4.22 ± 0.46 µM and α value of 
1.01 (Figure 3.11, equation 2 in Methods and Materials). 
 
TASPIN-1 treatment recapitulates the biology of the genetic loss of Taspase1 
As the initial screen employed to identify TASPIN-1 specifically identifies bioactive molecules, we 
assessed the molecular effects on cells treated with TASPIN-1 to determine whether TASPIN-1 
could recapitulate the effects resulting from the acute, genetic deficiency of Taspase1.  MYC and 
RASG12V transformed murine embryonic fibroblasts (MEFs) generated from Rosa26-
creERT;Taspase1f/- mice can be induced to excise the remaining allele of Taspase1 by induction of 
Cre-recombinase activity by treatment with the estrogen analog 4-hydroxytamoxifen.  After the 
excision of and subsequent loss of Taspase1 expression, MYC-RASG12V transformed MEFs 
exhibit a proliferative block characterized by down-regulation of G1/S Cyclins, including Cyclin A 
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and Cyclin E2, with minimal increase in the upstream cyclin dependent kinase inhibitors (CDKIs) 
in contrast to that observed in the human cancer cell lines that lose Taspase1 expression by sh-
RNA.  Transformed fibroblasts that do not bear a conditional allele of Taspase1 (Rosa26-
creERT;Taspase1+/-) serve as a control for Cre-recombinase induction (Figure 3.12). 
 
Concordantly, treatment of primary MEFs with TASPIN-1 caused a dose-dependent inhibition of 
substrate cleavage, as assessed by disappearance of the MLLC180 cleavage product as well as 
the increase in non-cleaved TFIIAαβ and loss of the TFIIAα cleavage product (Figure 3.13).  Loss 
of Taspase1 substrate cleavage results in a corresponding loss of Cyclin A expression to the 
level seen in Taspase1-null MEFs (Figure 3.13).  Taken together, treatment with TASPIN-1 
recapitulates the Taspase1 null phenotype, suggesting that it can effectively inhibit Taspase1 
function in cells.  Furthermore, TASPIN-1 treatment of SV40-transformed MEFs preferentially 
prohibits proliferation of Taspase1-expressing cells rather than Taspase1-null cells.  As genetic 
loss of Taspase1 in MEFs causes decreased proliferation, the biological effects of TASPIN-1 
likely due, at least in part, to on-target Taspase1 inhibition.  This is demonstrated by the restored 
sensitivity of Taspase1-null MEFs to TASPIN-1 treatment when reconstituted with Taspase1 
expression (Figure 3.13). 
 
TASPIN-1 is a Taspase1-specific anti-cancer drug 
Publicly available data from the NCI Developmental Therapeutics Program NCI60 cancer cell line 
panel anticancer drug screen yielded a distinct pattern of growth inhibition by 
NSC48300/TASPIN-1 (Shoemaker, 2006).  Remarkably, the sensitivity of individual cancer cell 
lines to TASPIN-1 correlates well with the expression of Taspase1 within certain subtypes of 
human cancer, namely breast and glioblastoma (Figure 3.14 and 3.15).  Our prior analysis of the 
NCI60 panel of cell lines reveals that many cancer cell lines highly express Taspase1 when 
compared to the non-transformed, immortalized fibroblast cell line hTERT-BJ1 (Takeda et al., 
2006b). In agreement with our prior study, which suggests that cell lines which express higher 
levels of Taspase1 are more dependent on Taspase1 for continued proliferation and survival, the 
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ability of TASPIN-1 to cause growth inhibition (GI50) correlates well with the relative expression of 
Taspase1 in breast cancer and glioblastoma cell lines (Figure 3.14 and 3.15).   
 
Comparison of MCF7 and MDA-MB-231, high and low Taspase1-expressing breast cancer cell 
lines, respectively, with acute loss of Taspase1 expression mediated by Taspase1 shRNA 
reveals that MCF7 is more sensitive to Taspase1 loss than MDA-MB-231.  Taspase1 down-
regulation results in a more severe proliferative defect in MCF7, as exhibited by decreased cell 
count compared to control cells.  Moreover the proportion of actively proliferating cells is 
decreased specifically in MCF7 with Taspase1 deficiency as determined by propidium iodide 
staining (Figure 3.16).  Accordingly, MDA-MB-231 is less sensitive to TASPIN-1.  Similarly, U251 
glioblastoma is much more sensitive to TASPIN-1 than the Taspase1-low line SF295 (Figure 
3.15).  Other cancer cell lines in the NCI60 have varying degrees of correlation between 
Taspase1 expression and TASPIN-1 mediated growth inhibition (data not shown). 
 
The striking correlation between Taspase1 expression and TASPIN-1 sensitivity, taken with our 
studies demonstrating that Taspase1 function is critical to tumor maintenance, suggests that 
Taspase1 is the major target of TASPIN-1 in blocking cancer cell growth.  Even so, due to its 
chemically simple composition, TASPIN-1 likely targets more than one cellular protein or 
pathway. Indeed, NSC48300 was recently shown to inhibit autotaxin, which is an extracellular 
protein involved in cellular migration (Saunders et al., 2008a).  Autotaxin catalyzes the conversion 
of lysophoshpatidylcholine (LPC) to lysophosphatidic acid (LPA), which is a potent phospholipid 
mediator of tumor and non-tumor cell motility, cellular proliferation, and tumor cell survival 
(Contos et al., 2000; Hoeglund et al., 2010).  Treatment with LPA, which is downstream of 
autotoxin, at levels shown to promote migration in both breast and glioblastoma cell lines (Samadi 
et al., 2009; Saunders et al., 2008b) does not rescue the inhibition of growth resulting from 
TASPIN-1/NSC48300 treatment (Figures 3.14 and 3.15).  Therefore, the generalized anti-tumor 
activity of TASPIN-1/NSC48300 is likely not to be due to the inhibition of autotaxin, rather it is 
more likely due to inhibition of Taspase1. 
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In vivo studies and other future directions 
The general strategy for in vivo assessment of NSC48300/TASPIN-1 utilizes both xenografted 
established human cancer cell lines as well as mice genetically engineered to spontaneously 
develop tumors.  Though the benefits of using spontaneous tumor models are clear—that they 
are genetically defined tumors (with a discreet initiating event), are anatomically correct, have no 
host-tumor mismatch, and have an intact immune system/tumor interface—there are multiple 
benefits to using an orthotopic engraftment model.  Most notably, the use of human, rather than 
murine cancers, more accurately represents human tumors and consequent tumor response to 
experimental therapy.  Xenograft models, in general, are well-suited for pre-clinical drug studies 
because of their high penetrance, synchrony, and ease of assessment, though they suffer from 
the lack of stepwise genetic changes that occur in development of the tumor in the animal.  This 
combined with the accrual of genetic and epigenetic alterations due extended in vitro culture often 
results in the cancer cell line not being able to accurately recapitulate the histology of the original 
tumor (Fomchenko and Holland, 2006).  Nevertheless, the degree of control offered by xenograft 
models makes it a tenable system to do the initial in vivo assessment of NSC48300/TASPIN-1. 
 
Because breast cancer cell lines respond to TASPIN-1 in a Taspase1-dependent manner, an 
MMTV-Neu transgenic mouse model system was employed to gauge the efficacy of TASPIN-1 in 
treating Her2/Neu driven breast tumors in vivo.  In vitro, the Her2 over-expressing line BT-474 
was the most sensitive of all tested breast lines to Taspase1 knockdown (Figure 3.16 B and C).  
The MMTV-Neu transgene drives mammary gland specific expression of the Her2/Neu 
oncogene, which results in the formation of breast tumors in female mice beginning at around 30 
weeks of age.  Breast cancer cell lines with ERBB2 amplifications tend to have higher expression 
of Taspase1 (Figure 3.16 A).  Furthermore, Taspase1 deficient MMTV-Neu mice (MMTV-
Neu;MMTV-Cre;T1f/f) are resistant to tumor formation, suggesting that Taspase1 is a critical 
permissive factor for Neu-mediated breast tumorigenesis but not in MMTV-Wnt-driven tumors in a 
similar system (B. A. Van Tine, unpublished data).  Female mice with established tumors 
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measuring 1cm in the long dimension were initiated on a regiment of TASPIN-1 at 1, 2.5, and 
5mg/kg intravenously through the lateral tail vein.  There was no overt toxicity in mice, other than 
an apparent injection site necrosis.  Tumors initially decreased in volume, as determined by 
caliper measurement, and then remained stable.  Injections were discontinued when the tail vein 
became hard to inject into after around four doses.  At current doses and formulation, there is an 
in vivo regression and cytostasis for Neu breast tumors and no change in MMTV-Wnt-driven 
tumors (data not shown).  Though these results are preliminary, they hold promise for TASPIN-1 
as a tenable lead compound for treatment of ERBB2 over-expressing tumors, while lacking non-
specific toxicity as shown by the lack of response in MMTV-Wnt tumors.  Mechanistically, it is 
interesting that though Her2/Neu over-expressing breast cell lines generally have high Taspase1 
expression, MCF7 appears to express Taspase1 at higher levels, suggesting that the 
Her2/Taspase1 axis is particularly important in Her2/Neu dependent tumors, while in non-
Her2/Neu amplified tumors have a different mechanism for Taspase1 dependence. 
 
Glioblastoma cell lines, like the breast cancer cell lines, respond to TASPIN-1 with sensitivity that 
correlates with Taspase1 expression.  Since there are very few drugs available for glioblastoma 
treatment, identification of new therapeutic targets and compounds to treat glioblastoma is of 
great importance.  To test the effect of TASPIN-1 on glioblastoma, U251 transduced with a firefly 
luciferase and green fluorescent protein fusion protein (fLuc-GFP plasmid a generous gift from D. 
Piwnica-Worms) retrovirus was subcutaneously engrafted into the flanks of NOD-scid/IL2Rγ-/- 
mice.  Following engraftment, mice were initiated on a 2.5mg/kg intravenous regimen of 
NSC48300/TASPIN-1, administered every other day, resulting in decreased tumor growth 
compared to vehicle-treated control (Figure 3.17). 
 
To assess the ability of TASPIN-1 to kill glioblastoma in its native site, U251-Fluc/GFP was 
orthotopically engrafted into the white matter of immunodeficient NOD/SCID/IL2Rg null mice 
under stereotaxic guidance.  Mice were initiated on a either 2.5mg/kg or 5mg/kg intravenous 
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TASPIN-1 regimen, administered every other day.  Tumor growth was monitored by 
bioluminescence.  Whether this will result in tumor regression is still being investigated. 
 
Gaining access to the CNS is a significant challenge for targeting therapies to disorders across 
the blood-brain barrier (BBB).  Roughly all large-molecule and over 98% of small molecule drugs 
are excluded by the BBB.  Though it is difficult to predict which specific small molecule will cross 
the BBB, there are a few characteristics associated with drugs known to cross the BBB, including 
a molecular mass (less than 400-500 Da) and formation of 10 or fewer hydrogen bonds with 
water.  Increases in mass (and hence, surface area) are strongly correlated with exclusion from 
the BBB, and increased lipid solubility has little effect on permeation of the BBB when the surface 
area is higher (Pardridge, 2005).   
 
Arsenic-containing molecules have been described to cross the blood brain barrier.  Arsenic 
trioxide (As2O3), used to treat relapsed acute promyelocytic leukemia (APL), has been shown to 
cross the blood brain barrier in the treatment of CNS relapse of APL (Au et al., 2006).  Although 
this is the case, there are significant differences between arsenic trioxide and TASPIN-1.  The 
physical properties of NSC48300/TASPIN-1, with a molecular weight of 416 g/mol, hydrophobic 
core, and 10 total hydrogen bond donor/acceptors, place it near the limits of compounds that are 
known to permeate the BBB.  Common solvents like dimethylsulfoxide (DMSO) and non-ionic 
surfactants like Tween 80 can facilitate passage through the BBB (Azmin et al., 1985; Broadwell 
et al., 1982).  Though TASPIN-1 delivery in this vehicle may increase the likelihood of a 
therapeutic dose in the CNS, increased or repeated dose of intravenous TASPIN-1 did not inhibit 
tumor growth in initial studies.  Whether TASPIN-1 gains access to the CNS in meaningful 
quantities remains to be addressed through further testing, which involves repeated sampling the 
CSF and either mass spectroscopy, HPLC, or other method to monitor the accumulation and 
clearance of TASPIN-1. 
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It is important to note that aside from the injection site necrosis, there was no overt toxicity 
observed in mice treated with repeated doses of TASPIN-1—they maintained normal activity, 
body weight, and blood count.  Studies are underway to determine the pharmacokinetics of 
TASPIN-1 as well as changes in serum values in the basic metabolic panel (BMP).  Acute 
deletion of Taspase1 in Mx1-cre;Taspase1f/- in adult mice is well tolerated in both male and 
female mice over the long term (>16 weeks after cre recombinase induction, A. Searleman, 
unpublished data).  Though Taspase1 is critical for murine embryonic development, it appears to 
be largely dispensable to normal health in adult mice.  Concordant with the classification of 
Taspase1 as a non-oncogene addiction protease, it seems that certain biological circumstances, 
like cancer, exhibit increased reliance on Taspase1 function and hence are exquisitely sensitive 
to Taspase1 loss.  This idea hearkens back to the original description of HSF1 as a non-
oncogene addiction factor in which HSF1 deficient mice were overtly normal and only exhibited 
pathology in situations of increased reliance on normal HSF1 function, like in situations of 
proteotoxic stress, yet were resistant to tumor formation (Dai et al., 2007a; Solimini et al., 2007).  
The defining feature—the relative of insensitivity of normal tissues compared to the sensitivity of 
tumors—of non-oncogene addiction factors results in a therapeutic window which makes 
inhibition of the non-oncogene addiction protease Taspase1 a promising new development in 
cancer therapy. 
 
The identification of NSC48300/TASPIN-1 as a specific inhibitor of Taspase1 is of potential 
clinical significance.  We previously described the critical importance of Taspase1 in maintenance 
of tumor proliferation and survival, and we further demonstrate that TASPIN-1 treatment can 
inhibit cancer cell proliferation in vitro and in vivo.  Although presence of arsonic acid may limit 
the clinical application of this particular compound because of potential non-specific toxicity, 
structural determination of the Taspase1-TASPIN-1 complex would assist the future development 
of Taspase1 inhibitors for cancer therapy. 
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3.4 FRET-based screening reveals further leads for Taspase1 inhibitors 
 
The tyrphostin family of tyrosine kinase inhibitors inhibit Taspase1 
In collaboration with the NCI DTP, we screened the Library of Pharmacologically Active 
Compounds (LOPAC 1280), which consists of 1,280 compounds that have described 
pharamacological actions, including kinase inhibitors, inducers of cellular stress, and antibiotics 
among others.  Adaptation of the FRET-based kinetics assay as an endpoint assay converts the 
detailed kinetics assay into a useful method for high throughput screening method to identify 
inhibitors of in vitro Taspase1 proteolysis of the FRPR substrate.  Dose-dependent decrease in 
fluorescence endpoint reading is scored as a positive hit for Taspase1 inhibition, which we 
subsequently validate using the radiographic in vitro cleavage assay.  Interestingly, the tyrphostin 
family of tyrosine phosphorylation inhibitors had multiple members that were able to inhibit 
Taspase1 to different degrees (Figure 3.18).  The tyrphostin family of inhibitors appears to 
irreversibly inhibit Taspase1 as inhibition of Taspsae1-mediated proteolysis of the radiographic 
MLL reporter increased with longer pretreatment times of Taspase1 with the tyrphostin (Y. Lee 
unpublished data).  Though Tyrphostin AG538 appears to be a more potent inhibitor of Taspase1 
than TASPIN-1, it may suffer from off-target effects, as it is known to be a potent inhibitor of IGFR 
(Blum et al., 2000).  As such, the application of tyrphostins as clinical inhibitors of Taspase1 
requires further investigation. 
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3.5  Methods and materials 
 
Radiographic in vitro cleavage assay 
To assess Taspase1 cleavage in vitro, an MLL cleavage reporter with a cleavage site 1 (CS1) 
mutation was generated, representing aa 2500-2800 of MLL1.  Mutation of CS1 by substitution of 
Asp-Gly with Ala-Ala at aa 2666 results in non-cleavage at CS1 but retention of CS2, generating 
two fragments p33 and p12 from the p45 non-cleaved substrate.  The MLL cleavage reporter was 
transcribed and translated in vitro in the presenence of 35S-methionine using the TNT rabbit 
reticulocyte lysate system according to the manufacturer’s protocol (Promega, Madison, WI).  
Cleavage assays were performed in a total volume of 25 microliters with cleavage buffer (20mM 
HEPES, pH 7.9, 5mM MgCl2, 20mM KCl, 10% sucrose, and 2mM DTT) with 15ng recombinant 
Taspase1 pre-incubated with DMSO or appropriate amount of yzm peptide derivative (10, 100, 
500μM) for 30 minutes at 30˚C before addition of 0.1 microliters of MLL reporter substrate for an 
additional 30 minutes at 30˚C.  Reactions were resolved on  10% Bis-Tris NuPage gels in MES 
buffer (Invitrogen, Carlsbad, CA).  Gels were fixed in 25% isopropanol/10% acetic acid for 30 
minutes followed by signal amplification for 30 minutes using Amplify solution (G.E. Healthcare 
Life Sciences, Piscataway, NJ).  Gels were dried at 80˚C for 1h and exposed to BioMax MR film 
(Kodak). 
 
FRET-based kinetics assay 
A quenched fluorescent probe for Taspase1 activity (FRPR) was generated by conjugating the N-
terminus with a 7-methoxycoumarin-4-acetyl (MCA) fluorophore and a dinitrophenyl (DNP) 
quencher at the C-terminus of the sequence Lys-Ile-Ser-Gln-Leu-Asp-Gly-Val-Asp-Asp, which 
represents the cleavage site 2 (CS2) sequence of MLL1 (Tufts University Core Facility, Boston, 
MA).  Reactions were conducted in reaction buffer (100mM HEPES, pH 7.9, 10% sucrose, 1mM 
DTT) in the presence of TASPIN-1 or vehicle control (DMSO).  For inhibition studies, recombinant 
Taspase1 was pre-incubated with TASPIN-1 for 30 minutes at room temperature before initiation 
of the reaction by addition of FRPR to a final concentration 15μM FRPR and 100nM Taspase1, 
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respectively.  Taspase1 activity was monitored by recording the accumulation of emitted 
fluorescence signal (λexcitation = 328nm, slit = 10nm and λemission = 393nm, slit = 10nm) over time 
using an LS55 fluorescence spectrometer with a 96-well plate adapter (Perkin Elmer, Inc., 
Waltham, MA).  Steady state rates were determined for each reaction and KM, KI, and IC50 values 
were determined using Prism software (GraphPad Software, Inc., La Jolla, CA), assuming 
Michaelis-Menten kinetics (Khan, et al. Structure 2005).  The following equations model the 
mechanism of inhibition, where α<<1 fits un-competitive inhibition, α=1 is fits non-competitive 
inhibition, and α>>1 fits competitive inhibition (Saunders et al., 2008b).  
 
𝑣[𝐸]𝑡𝑜𝑡 = 𝑘𝑐𝑎𝑡[𝑆]𝐾𝑀 + [𝑆] 
Equation 1: Briggs Haldane equation 
 
𝑣[𝐸]𝑡𝑜𝑡 = 𝑘𝑐𝑎𝑡[𝑆]𝐾𝑆 �1 + [𝐼]𝐾𝐼 � + [𝑆] �1 + [𝐼]𝛼𝐾𝐼� 
Equation 2: General Equation for inhibition 
 
Cell viability assay 
Wild type and Taspase1-null SV40-transformed MEFs were cultured in IMDM supplemented with 
10% FBS, 100U/mL penicillin/streptomycin, 2mM L-glutamine, 1mM sodium pyruvate, and 1mM 
non-essential amino acids (Invitrogen, Carlsbad, CA).  Five thousand cells per well were plated 
16h before drug treatment in 96-well plates.  After 48h of drug treatment, an MTT cell viability 
assay was performed as recommended by the manufacturer (Roche, Indianapolis, IN).  Cell 
viability was expressed as a fraction of control (DMSO) treated cells. 
 
Xenograft assay 
A reporter cell line was generated from the glioblastoma cell line U251 by transduction with an 
amphotropic retrovirus encoding both GFP and firefly luciferase.  Cells were harvested and 
resuspended in 1:2 suspension of growth factor-depleted matrigel and RPMI and one million cells 
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were engrafted subcutaneously in each flank of male NOD-scid IL2Rγ-/- mice between 6-8 weeks 
of age.  Tumors were engrafted on day 0 and treated with an IV preparation of NSC48300 at 
2.5mg/kg every other day starting at day 1.  Tumor growth was monitored by bioluminescence 
imaging using an IVIS 100 system. 
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3.6   Figures 
 
 
 
 
 
 
 
Figure 3.1.  Structural characteristics of Taspase1 and its substrates. 
 
A, Ribbon diagram of the Taspase1 active heterotetramer crystal structure (PDB 2A8I) in an 
orientation where the major features are visible.  The N-terminal catalytic threonine (T234) is en 
face on the green protomer, while the α/β/β/α structure is clearly visible in the blue protomer, 
though its threonine nucleophile is facing into the page.  B, Cleavage site consensus alignment of 
known mammalian Taspase1 substrates reveals significant conservation of the cleavage site 
residues (ClustalW2, http://www.ebi.ac.uk/Tools/clustalw2).  Clevage occurs after the aspartate 
in QVDG. 
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Figure 3.2.  Assessing Taspase1 inhibition I—the in vitro cleavage assay. 
 
An in vitro transcribed and translated (IVTT) fragment of MLL was synthesized using a rabbit 
reticulocyte lysate system, in the presence of 35S-methionine so that newly synthesized proteins 
could be detected by autoradiography.  This fragment of MLL, from aa 2500 to 2800, 
encompasses the endogenous cleavage sequences CS1 and CS2, where CS1 is mutated by 
site-directed mutagenesis, leaving only CS2.  Upon introduction of recombinant Taspase1 
(rTaspase1), p45MLL reporter is cleaved at CS2, which is detected by autoradiography.  Inhibition 
of cleavage results in the accumulation of the p45MLL non-cleaved band, and decrease in the 
cleaved p33MLL product.  
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Figure 3.3.  Assessing Taspase1 inhibition II—the cell-based screening assay. 
 
The dual fluorescence proteolysis reporter (DFPR) consists of a fragment of MLL1 between 
aa2400 – 2900, which includes both endogenous Taspase1 cleavage sites (CS1 and CS2).  The 
N-terminus is fused to GFP and a nuclear export signal (NES), while the C-terminus is fused to 
dsRED2 and a nuclear localization signal.  When stably expressed in healthy 293T cells, the C-
terminal/red fragment can be clearly discerned from the N-terminal/green reporter fragment by 
their color and localization.  Inhibition of Taspase1 to levels that substantially prevent proteolysis 
of the reporter causes mislocalization of both GFP- and dsRED2-tagged fragments, 
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Figure 3.4.  Assessing Taspase1 inhibition III—the FRET based kinetics assay. 
 
The reporter FRPR is a short peptide representing the MLL1 CS2.  The N-terminus is conjugated 
to a methoxycoumaryl fluorphore (MCA), while the C-terminus is conjugated to a dinitrophenyl 
quenching group (DNP).  In its native state, incident excitatory light at λex=328nm does not 
produce an emission signal at λem=393nm .  When stably expressed in healthy 293T cells, the C-
terminal/red fragment can be clearly discerned from the N-terminal/green reporter fragment by 
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Figure 3.5.  HTI-9 is a competitive inhibitor of Taspase1 and cooperates with non-competitive 
inhibitor NSC48300/TASPIN-1. 
 
A, HTI-9 peptide inhibitor was determined to be a competitive inhibitor of Taspase1 using the 
modified version of the Briggs-Haldane equation (equation 3.2, methods and materials), where 
competitive inhibition has an α>>1.  HTI-9 is a relativey weak inhibitor of Taspase1, with a Ki = 
228±31μM.  B, Non-competitive inhibitor NSC48300/TASPIN-1 cooperates with HTI-9 to inhibit 
Taspase1 cleavage of the FRPR reporter.  Shown here is the reaction progress plot. 
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Figure 3.6.  Proof of principle in rational design of peptide inhibitors of Taspase1. 
 
A, Short peptide Taspase1 inhibitors are based on the cleavage site (CS2) sequence of MLL1 to 
engender specificity, for engagement of Taspase1 with various pharmacophores, including vinyl 
sulfones (yzm16, yzm18), vinyl ketone (yzm19), boronic acid (yzm49), and epoxyketone (yzm38).  
Norleucine (yzm22) is a control peptide.  These inhibitors were generated in collaboration with M. 
Bogyo and colleagues at Stanford University.  B, In vitro cleavage assay demonstrates inhibition 
of Taspase1 cleavage of the p45MLL reporter substrate with increasing doses of peptide inhibitor 
(10, 100, and 500μM). 
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Figure 3.7.  The vinyl sulfone yzm18 is a reversible inhibitor of Taspase1. 
 
A, Reversibility was determined by pre-incubation with yzm18 and Taspase1 with increasing time 
(15, 30, and 60 minutes) before introducing the p45MLL substrate.  Irreversible inhibition is marked 
by decreased ability to process substrate with longer pre-incubation times.  B, Band intensities for 
the radiographic cleavage assay were quantified using the STORM phosphorimaging system. 
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Figure 3.8.  The vinyl sulfone yzm18 is not a potent inhibitor of Taspase1 in vivo. 
 
The effect of yzm18 in vivo was assessed by incubation of with SV40-transformed wild type 
Taspase1 MEFs over 3 days before performing an MTT assay to assess viable cell mass.  Low 
concentration (0.1μM) yzm18 treated cells were assigned a value of 1.  
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Figure 3.9.  An in vitro screen identifies NSC48300/TASPIN-1 as a potent bioactive inhibitor of 
Taspase1. 
 
293T cells expressing DFPR were plated in 96-well plates the day before treatment with the NCI 
Diversity Set of 1900 compounds.  Hits were validated by the in vitro cleavage assay and 
subsequently evaluated for Taspase1 inhibition specificity using rCaspase8 (cysteine aspartase) 
and its proteolytic target Bid,  Of 1900 compounds, only NSC48300/TASPIN-1 was a bioactive 
and specific inhibitor of Taspase1.  Thanks goes to S. Takeda for contributing work to this screen. 
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Figure 3.10.  Structural features of TASPIN-1 define its Taspase1 inhibitory activity. 
 
A, TASPIN-1 is a potent inhibitor of in vitro Taspase1 reporter cleavage, with an IC50 ~ 5μM.  B, 
To determine if TASPIN-1 is a reversible or irreversible inhibitor of Taspase1, TASPIN-1 was pre-
incubated with Taspase1 for the indicated times before addition of radiolabeled p45MLL.  C, 
Pharmacophore modeling identifies putative Taspase1 inhibitors based on the TASPIN-1 
pharmacophore.  In vitro cleavage of p45MLL was used to test the efficacy of inhibition.  Thanks 
goes to Y. Lee for contributing this figure. 
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Figure 3.11.  NSC48300/TASPIN-1 is a non-competitive inhibitor of Taspase1. 
 
A, Non-linear regression of reaction progress curves of the FRET-based kinetics assay with 
TASPIN-1 treatment revealed that Taspase1 is non-competitive inhibitor of Taspase1 (α=1.01, 
equation 2 in the Methods and materials section) with a Ki of 4.24 ± 0.46μM.  B, Lineweaver-Burk 
plot indicates that unlike Vmax, KM does not vary with Taspin-1 concentration, consistent with non-
competitive inhibition. 
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Figure 3.12.  Molecular consequences of genetic loss of Taspase1. 
 
MYC/RASG12V transformed primary MEFs bearing a conditional allele of Taspase1 (R26-
creERT;T1f/-) or control (R26-creERT;T1+/+) were subjected to a 6h pulse of 500nM of 4-OH 
tamoxifent to induce Cre-recombinase activity.  Lysates were generated 48h after treatment and 
immunoblotted with the indicated antibodies. 
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Figure 3.13.  TASPIN-1 treatment recapitulates the Taspase1-null phenotype. 
 
A, Primary Taspase1 wild type or null MEFs were subjected to treatment with the indicated 
concentration of TASPIN-1.  Lysates were generated 24h after treatment and immunoblotted with 
the indicated antibodies.  B, Taspase1 null SV40-transformed fibroblasts were reconstituted with 
various amounts of hTaspase1 by retroviral transduction and subjected to treatment with 
TASPIN-1.  Viable cell mass was determined by MTT assay.  Lysates were generated form wild-
type, Taspase1-null, and Taspase1 reconstituted SV40-transformed MEFs and subjected to 
Taspase1 immunoblot and actin immunoblot to demonstrate equal loading 
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Figure 3.14.  TASPIN-1 sensitivity is correlated with relative Taspase1 expression level in breast 
cancer cell lines. 
 
A, Comparison of normalized Taspase1 protein expression with the GI50 concentration of 
TASPIN-1 demonstrated that the sensitivity of growth inhibition to TASPIN-1 correlates well with 
the protein expression of Taspase1 breast cancer cell lines. Protein expression data of Taspase1 
in NCI60 cell lines has been described (Takeda et al., 2006b), while GI50 data is obtained from 
the NCI DTP website (http://dtp.nci.nih.gov). The protein expression and the GI50 is compared to 
the mean of all five breast cancer cell lines and presented as a fraction of the standard deviation. 
GI50 denotes growth inhibition 50%.  B, To exclude effects of autotoxin inhibition, breast cancer 
cell lines were treated with 100nM LPA or mock treated in addition to TASPIN-1 treatment.  MTT 
assay was performed after two days of treatment to determine viable cell mass. 
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Figure 3.15.  TASPIN-1 sensitivity is correlated with relative Taspase1 expression level in brain 
cancer cell lines. 
 
A, Comparison of normalized Taspase1 protein expression with the GI50 concentration of 
TASPIN-1 demonstrated that the sensitivity of growth inhibition to TASPIN-1 correlates well with 
the protein expression of Taspase1 central nervous system (CNS) cancer cell lines. Protein 
expression data of Taspase1 in NCI60 cell lines has been described (Takeda et al., 2006b), while 
GI50 data is obtained from the NCI DTP website (http://dtp.nci.nih.gov). The protein expression 
and the GI50 is compared to the mean of all five brain cancer cell lines and presented as a fraction 
of the standard deviation. GI50 denotes growth inhibition 50%.  B, To exclude effects of autotoxin 
inhibition, brain cancer cell lines were treated with 100nM LPA or mock treated in addition to 
TASPIN-1 treatment.  MTT assay was performed after two days of treatment to determine viable 
cell mass. 
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Figure 3.16.  Breast cancer cell lines expressing higher Taspase1 are more sensitive to 
Taspase1 loss. 
 
A, Comparison of HER2 positive cell lines with HER2 negative lines by Western blot.  Lysates 
were subjected to immunoblot for HER2, Taspase1, and actin blot for comparison.  B, Taspase1-
shRNA transduced cells were plated at 105 cells per well in 6-well plates and counted 4 days after 
plating.  Control-shRNA cell count average was assigned the value 1 for comparison.  C, 
Proliferative status for cell lines expressing Taspase1- or control-shRNA was determined by PI 
staining for DNA content and subsequent FACS analysis. 
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Figure 3.17.  Glioblastoma xenografts respond to TASPIN-1 treatment in vivo. 
 
To gauge the effect of Taspase1 inhibition in vivo, a U251 glioblastoma cell line expressing a 
firefly luciferase and GFP fusion protein was injected subcutaneously into the flanks of NOD-scid 
IL2Rγ-/- mice (day 0) and treated with an IV preparation of NSC48300/TASPIN-1 at 2.5mg/kg 
every other day starting at day 1.  Tumor growth was monitored by bioluminescence imaging. 
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Figure 3.18.  Tyrphostins are potent inhibitors of Taspase1 in vitro. 
 
Library of pharmacologically active compounds (LOPAC 1280) screening from the FRET-based 
assay identified a family of receptor tyrosine kinase inhibitors that potently inhibit Taspase1.  The 
table is a comparison of Taspase1 inhibition in a FRET-based determination of IC50. 
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4.1   Future directions: in vitro studies 
 
Balancing proliferation and apoptosis 
This body of work represents the first establishment of a role for Taspase1, a non-oncogene 
protease, in tumor maintenance.  Because the nature of non-oncogene addiction factors is, by 
definition, insufficient to drive tumorigenesis by itself, it is particularly challenging to define what 
functions are critical to the ability of such factors to mediate efficient tumorigenesis.  It is clear, 
though, that Taspase1 is required for oncogenic transformation and maintenance of tumor 
phenotypes.  Taspase1 deficiency in non-transformed, primary murine fibroblasts first established 
the role of Taspase1-mediated proteolysis of MLL in the orchestration of cell cycle progression 
through its obligate role in driving the expression of key Cyclins E, A, and B (Takeda et al., 
2006b).  In certain tumor types like glioblastoma, in contrast with non-transformed MEFs, 
Taspase1 also regulates cellular survival.  We establish that Taspase1 regulates the 
deubiquitinase (DUB) protein USP9X, which was recently described as a critical regulator of the 
protein stability of the anti-apoptotic BCL-2 family member MCL-1 (Schwickart et al., 2010).  
Taspase1 deficiency decreased proliferation in cancer cell lines in which Taspase1 is normally 
highly expressed, though unlike in MEFs, Cyclin E and A expression remain unchanged.  Rather, 
the CDKI p27KIP1 was up-regulated with acute Taspase1 deficiency, which is consistent with the 
G1/S phase cell cycle block observed with Taspase1 loss in cancer cell lines. 
 
Pleiotropic regulation of proliferation and death is commonly observed in oncogenic signaling, as 
well-established by the role of the transcription factor MYC in regulating both.  Interestingly, all of 
the described substrates for Taspase1 are nuclear factors involved broadly in regulating 
transcriptional programs, giving us some insight into how a single protease might sufficiently 
regulate both proliferative and apoptotic programs, and, as will likely be demonstrated later, many 
other important biological programs. 
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Taspase1 and the regulation of Cyclin-dependent kinase inhibitors p16INK4A, p21CIP1, and p27KIP1 
Though Taspase1 regulates both Cyclins and the upstream Cyclin-dependent kinase inhibitors 
(CKDIs), it is unclear whether the cleavage of MLL has a role in modulating CDKI expression.  
Direct binding of MLL, through E2F transcription factors, at Cyclin promoters has been 
demonstrated, resulting in increased histone H3 lysine 4 (H3K4) trimethylation, which is an 
epigenetic mark associated with positive transcriptional activity.  Taspase1 loss results in 
hypomorphic H3K4 methyltransferase activity and decreased H3K4 methylation at the Cyclin E 
promoter.  Yet, MLL targeting to the p16INK4A locus is increased in Taspase1 deficiency and the 
H3K4 methylation remains unchanged (Takeda et al., 2006b). 
 
It seems counterintuitive that though MLL non-cleavage is associated with hypomorphic 
transactivation capabilities, loss of Taspase1 causes an increase in p16INK4A transcript.  
Regulation of p16INK4A is primarily through transcriptional control, and many possibilities exist for 
why we observe p16 transcript and protein up-regulation with Taspase1 deficiency.  First, it is 
possible that increased targeting of non-cleaved MLL to the p16INK4A promoter simply displaces its 
functional antagonist BMI-1, which is an oncogene known to repress p16INK4A transcription 
(Jacobs et al., 1999).  The MLL N-terminal repression domain has been shown to interact with 
BMI-1 (Xia et al., 2003), which brings up the interesting possibilities that non-cleaved MLL may 
displace BMI-1, lose interaction with BMI-1 (and hence MLL may become hypo-functional in its 
gene-repressive activity rather than gaining a trans-activating property), or cause an allosteric 
inactivation of BMI-1.  A simple approach to addressing the role of BMI-1 in regulating the INK4A 
locus in the absence of Taspase1 would be to assess whether the occupancy of the p16INK4A 
promoter by BMI-1 is changed.  Alternatively, non-cleaved MLL could bind a different set of co-
factors than cleaved MLL, rendering either enhanced trans-activation capability or loss of 
transcriptional repression in a BMI-1 independent manner.  For instance, MLL has been shown to 
interact with the DDB1/CUL4A ubiquitin ligase machinery, which is required for RAS-induced 
p16INK4A induction, though the biochemical mechanism explaining this induction remains unknown 
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(Kotake et al., 2009).  Finally, it is also possible that substrates other than MLL, like TFIIA or ALF 
regulate the expression of p16INK4A. 
 
Transcript levels of another CDKI, p21CIP1 are elevated in Taspase1-null MEFs, which is likely 
dependent on the activation of a canonical p53-dependent pathway.  TP53 is frequently mutated 
in cancer cell lines, and shRNA-induced Taspase1 loss increases p21 expression an appreciable 
amount only in the lung adenocarcinoma line, A549, which is the singular cell line in the tested 
panel that harbors wild type TP53.  Whether Taspase1 regulates the p53 pathway is a matter for 
further study. 
 
Perhaps the most important Taspase1-regulated CDKI is p27KIP1.  Sharing significant homology 
to p21CIP1, the cyclin dependent kinase inhibitor p27KIP1 potently inhibits Cyclin D1-cdk4 and 
Cyclin E-cdk2 complexes at the G1/S cell cycle phase boundary.  A distinguishing feature of 
p27KIP1, however, is that its expression responds to mitogenic stimuli, as its levels are kept high in 
quiescent cells, but drop rapidly upon mitogen stimulation.  Translational and post-translational 
mechanisms are implicated in p27 regulation, including negative feedback by Cyclin E/cdk2 
phosphorylation and subsequent inactivation by proteasomal degradation (Sherr, 1996).  Protein 
expression of p27KIP1 is regulated post-translationally by the ubiquitin-proteasome pathway and 
depends on the action of the E3-ubiquitin ligase SKP2, which recognizes the phosphorylated 
state of p27KIP1 conferred by Cyclin E/cdk-2 (Carrano et al., 1999; Pagano et al., 1995).  The 
transcription factors of the forkhead family, including AFX (MLLT7/FOXO4), FKHR (FOXOA1), 
and FKHR-L1 (FOXO3A) regulate p27KIP1 transcript through RAS/PI3K (Dijkers et al., 2000; 
Medema et al., 2000).  Further integration with growth factor pathways occurs through the direct 
phosphorylation at T157 of p27 by AKT, which causes the retention of p27 in the cytoplasm and 
titrating it away from its target Cyclins, thereby preventing G1 arrest (Liang et al., 2002; Shin et 
al., 2002; Viglietto et al., 2002).  Recently, other oncogenic kinases such as Src, Lyn, and BCR-
ABL, have been implicated in the direct phosphorylation of p27 tyrosine residues to regulate its 
stability as well as impairing its ability to effectively inhibit the Cyclin E-cdk2 kinase (Chu et al., 
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2007; Grimmler et al., 2007), which suggests that p27 inactivation is an important task that 
oncogenes must accomplish in the process of transformation. 
 
Taspase1 down-regulation in cancer cell lines that express high basal levels of Taspase1 
uniformly up-regulate p27KIP1.  Transcript levels in U251 glioblastoma cells are up-regulated by 
roughly 1.5 fold, while protein is concomitantly stabilized.  These two features are reminiscent of 
AFX over-expression in MEFs (Medema et al., 2000).  It is therefore possible that Taspase1 
regulates p27KIP1 expression indirectly through forkhead transcription factors.  Forkhead 
transcription factors, like FOXO3A, are regulated in part by growth factor signaling through the 
PI3K/AKT pathway by phosphorylation and cytoplasmic retention (Brunet et al., 1999).  
Preliminary evidence suggests that Taspase1 may regulate p27 in a PI3K dependent manner.  
Glioblastoma cell line U251 treated with U0126 (MEK/ERK inhibitor) or LY294002 (PI3K inhibitor) 
up-regulate p27KIP1.  In Taspase1 deficiency, which causes an up-regulation of p27 level 
compared to the control, further increase in p27KIP1 is seen only with MEK inhibition and not PI3K 
inhibition, suggesting that Taspase1 is not downstream of MEK in p27 regulation, but may be 
downstream of PI3K (data not shown).  Alternatively, because Taspase1 is involved in the 
processing of multiple transcription factors, it is possible that Taspase1 may involve other factors 
important in p27 degradation, including E3 ligases SKP2 and KPC (Carrano et al., 1999; Hara et 
al., 2005; Kotoshiba et al., 2005). 
 
Taspase1 and the regulation of the anti-apoptotic BCL-2 family member MCL-1 
In primary cells, Taspase1 does not appear to regulate cell death, even upon application of death 
stimuli, and Western blotting reveals that MCL-1 does not depend on Taspase1 expression 
(Figure 4.3).  It is only in cancer cell lines in which we see MCL-1 regulation, and even then this 
phenomenon was only observed in a specific subset of cell lines.  In U251 and SK-MEL-2 
glioblastoma and melanoma cell lines, respectively, Taspase1 deficiency causes a significant 
destabilization of MCL-1 protein.  However, among the other cell lines tested, only the A549 lung 
adenocarcinoma line exhibits appreciable MCL-1 down-regulation, and even then, the down-
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regulation is modest (data not shown).  Though Taspase1 is down-regulated with high efficiency 
with sh-RNA targeting, there is still residual Taspase1 protein as assessed by Western blot, and 
transcript levels persist at roughly 20% of control (data not shown).  Taspase1 is a highly efficient 
enzyme, though it seems to more efficiently process certain substrates over others, as Taspase1 
sh-RNA can deplete Taspase1 expression enough to fully inhibit TFIIAαβ cleavage, but only 
partially inhibit MLL cleavage.  Since genetic studies in mice demonstrate that Taspase1 is the 
obligate protease for MLL and TFIIAαβ cleavage, it is likely that some Taspase1-deficiency 
phenotypes like MCL-1 regulation may be masked by insufficient inhibition of Taspase1 function 
by this particular strategy. 
 
We identified USP9X, a deubiquitinase that is known to stabilize MCL-1, as a Taspase1-regulated 
gene.  There are approximately 100 enzymes in the DUB family which play diverse roles in 
cancer progression, from stabilizing receptor tyrosine kinases like EGFR and MET, to regulation 
of the MDM2/p53 pathway, and the regulation of NF-κB signaling (Lopez-Otin and Hunter, 2010).  
USP9X is located on the X-chromosome and is known to deubiquitinate Survivin, regulating its 
association with centromeres, and hence chromosome alignment and segregation, without 
affecting its protein degradation (Vong et al., 2005).  Recently, USP9X was described to remove 
ubiquitin from MCL-1, stabilizing the protein.  Suppression of USP9X by sh-RNA knockdown 
resulted in the destabilization of MCL-1 protein in multiple myeloma cells, in which over-
expression of MCL-1 is a poor prognostic factor (Schwickart et al., 2010).  Decreased levels of 
MCL-1 resulting from USP9X deficiency increased cancer cell susceptibility to ABT-737, which 
inactivates BCL-2 and BCL-XL, but not MCL-1.  We demonstrated that Taspase1-deficient 
glioblastomas have impaired transcription of USP9X, enriched levels of ubiquitinylated MCL-1, 
and consequent increase in sensitivity to ABT-737 in vitro and in vivo.  Importantly, Dixit and 
colleagues noted that increased USP9X transcript correlated with increased protein in diffuse 
large B-cell lymphoma (DLBCL) cell lines, suggesting that USP9X protein expression is controlled 
at the transcriptional level (Schwickart et al., 2010), just as we demonstrated in the context of 
Taspase1 deficiency. 
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It is interesting to note that U251 and SK-MEL-2 lose MCL-1 expression to a much higher degree 
than A549 with Taspase1-loss, while in other cancer cell lines MCL-1 levels remain rather 
unperturbed.  To gain clues about the mechanistic details of Taspase1-mediated MCL-1 
regulation, multiple questions must be addressed.  The first piece of information to be acquired, 
however, is the USP9X expression level of each cell line upon Taspase1 knockdown.  One 
possibility is that the Taspase1/USP9X axis is disrupted in resistant cell lines.  Additionally, we 
have ruled out many of the other known mechanisms by which MCL-1 stability is regulated, since 
Taspase1 knockdown in U251 did not respond to GSK-3β inhibition, did not down-regulate 
described E3-ubiquitin ligases MULE or β-TRCP, nor did it down-regulate the stabilizing 
chaperone TCTP.  A remaining possibility is that ERK-mediated phosphorylation of the MCL-1 
PEST domain may dictate Taspase1-mediated control of MCL-1 stability (Domina et al., 2004). 
Because Taspase1 regulates transcription factors, USP9X expression may be modulated by one 
of the described Taspase1 substrates, including MLL1, MLL2, TFIIA, or ALF. 
 
The U251 and SK-MEL-2 cell lines also differ from the other cell lines in the panel by their 
embryonic origin.  Glioblastoma mulitforme is thought to be of astrocytic origin and melanomas 
from benign melanocytes.  Both of these cell lineages are derived from the neuroectoderm, while 
in contrast, the epithelium of colon, breast, lung, and prostate arise from the endoderm.  MEFs, 
on the other hand, are derived from the mesoderm.  Historical cancer classification has relied on 
this inherent and readily observable phenomenon, which provides the basis for categorization on 
particular differentiation states (classification of leukemias), tissue lineage (cancers of different 
tissue origins), embryonic germ layer (ectoderm-, mesoderm-, and endoderm-derived), and 
histological lineage (squamous carcinoma compared to adenocarcinoma) (Garraway and Sellers, 
2006).  Thus, the implication is that the developmental history of a cell determines the particular 
molecular constitution, whether by genetic or epigenetic means, from which tumors are formed 
and by which tumors can be dismantled.  In point of fact, there are no mutations in common that 
distinguish SKMEL2 and U251 from the other cancer cell lines examined (Table 2.1); however, 
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deregulated cellular programs arising from mutations, whether characterized or awaiting 
characterization in these cell lines, perhaps interact in a unique fashion with the distinct 
developmental makeup of the cell.  This, in turn, may dictate the observed difference in response 
to Taspase1 inhibition.  Consistent with this notion of “lineage addiction” mediated by broad 
epigenetic changes occurring in development (Garraway and Sellers, 2006), Taspase1 regulates 
broad-acting transcriptional regulators such as TFIIA and MLL.  MLL, in particular, is implicated in 
multiple developmental processes and is a key actor in the interplay between the Trithorax and 
Polycomb groups of developmental regulators.  MLL deregulation causes global epigenetic 
changes and gene expression changes in pathological conditions like cancer (Krivtsov and 
Armstrong, 2007).  To control for cellular context, and to better understand Taspase1-mediated 
regulation of MCL-1, additional glioblastoma and melanoma cell lines should be analyzed for their 
sensitivity to Taspase1 loss-induced MCL-1 destabilization. 
 
The role of Taspase1 in the natural history of a tumor 
Though we previously established that Taspase1 is required for tumorigenesis in vitro, it 
is unclear what function a protease like Taspase1 could play in tumorigenesis.  As a 
protease with no known signaling role, it is difficult to imagine that simple over-expression 
of a protease would confer tumorigenic capabilities, and indeed, over-expression of Taspase1 in 
conjunction with established oncogenes in primary MEFs, or supraphysiological expression of 
Taspase1 in immortalized NIH/3T3 fibroblasts does not confer a tumor phenotype (Figure 2.2).  
However, soft agar colonies from MEFs transformed by co-expression of complementary 
oncogenes MYC/RASG12V, E1A/RASG12V, and DNP53/RASG12V, which represent tumorigenic 
clones, uniformly express Taspase1 to a much higher level than the non-selected pool of 
transformed cells, which include non-tumorigenic clones (Figure 4.3).  Furthermore, Taspase1-
deficient MEFs are resistant to transformation by the same complementary oncogenes.  Taken 
together, this implies that oncogenic signaling programs, in order to fulfill the requirements of 
tumorigenesis, co-opt Taspase1 function to efficiently transform primary cells.  However, the 
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mechanism by which Taspase1 is co-opted as well as the effector functions of Taspase1 required 
to facilitate tumorigenesis and maintenance await description. 
 
The signals upstream of Taspase1 are still unknown.  However, in silico analysis of the Taspase1 
promoter indicates that multiple transcription factors bind in a conserved fashion between 
humans, mice, and other species.  The promoter analysis pipeline (PAP) (Chang et al., 2006) 
identified conserved MYC, HIF1-β/ARNT, and forkhead transcription factor sites, among others in 
the Taspase1 promoter region (Table 4.1).  Additionally, the intracellular domain of NOTCH1, was 
found to bind directly to the MYC promoter, resulting in the transactivation of MYC.  This opens 
up the possibility that NOTCH1 may indirectly regulate Taspase1 through MYC activity, though 
MYC binding to the Taspase1 promoter remains to be demonstrated.  In the same study, 
intracellular Notch was found to directly bind to the Taspase1 promoter by ChIP-on-chip assay.  
Treatment of T-ALL cell lines harboring activating NOTCH1 mutations with a γ-secretase inhibitor 
prevented NOTCH1 cleavage, resulting in markedly decreased promoter occupancy by NOTCH1, 
and decreased expression of, known targets HES1 and DELTEX1, as well as MYC and TASP1 
(Palomero et al., 2006).  Indeed, Taspase1 is highly expressed in T-cell lymphomas compared to 
other types of blood tumors (Figure 4.5).  Further investigation into the putative 
NOTCH1/Taspase1 pathway may reveal mechanistic insight to how Taspase1 is regulated and 
further delineate its role in development and cancer. 
 
4.2 Future directions: in vivo studies 
 
Taspase1 is over-expressed in multiple human cancers 
In vitro tumorigenesis, using the soft agar assay, revealed that Taspase1 expression is selectively 
up-regulated in tumorigenic clones of oncogene pair-transduced MEFs compared to the non-
selected pools of cells.  Evidence suggests that this phenomenon holds true in human 
tumorigenesis as well.  In a murine model of hepatocellular carcinoma (HCC) TASP1 was found 
to be a target of the HNF4α transcription factor, which elevated TASP1 transcript in tumors 
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compared to transgenic but pre-tumorigenic livers, while primary human HCC exhibited elevated 
Taspase1 protein (Niehof and Borlak, 2008).  Furthermore, in an analysis of candidate disease 
genes for glioblastoma, TASP1 transcript was enriched in glioblastoma but not in normal white 
matter (Scrideli et al., 2008).  This is consistent with our histological examination of glioblastoma 
tumor sections, which exhibited up-regulation of Taspase1 protein in tumor compared to 
histologically normal astrocytes from the same patient (Figure 2.6 and 2.15). 
 
Other tumor types were examined by immunofluorescence show similar increase in Taspase1 
protein, including in breast (Figure 4.5) and colon adenocarcinomas (Figure 4.6) as well as in 
melanomas (Figure 4.7).  Melanoma sections were compared to benign melanocytic nevi to 
gauge the difference in Taspase1 expression between benign and malignant melanocytes, using 
adjacent keratinocytes to normalize fluorescent signal.  In all of the tumors examined, Taspase1 
was localized primarily to a sub-nuclear compartment that co-localizes with the C23 marker for 
the nucleolus (Figure 4.5, 4.6, and 4.7).  This is surprising finding since Taspase1 was initially 
isolated from the light membrane and S100 fractions of 293T cells (Hsieh et al., 2003a).  In GFP-
Taspase1 over-expressing SV40-transformed MEFs, Taspase1 is localized diffusely in the 
nucleus as well as concentrated in the nucleolus (data not shown).  While in tumor sections, 
diffuse nuclear staining was in most cases low, and the presence of nucleoli nearly always 
accurately predicted the presence of Taspase1.  What function Taspase1 plays in the nucleolus 
is a matter of active investigation, but possibilities include the processing of nucleolus-restricted 
proteolytic targets, cryptic enzymatic activity (for example, activity more akin to its evolutionary 
heritage as an asparaginase), or that it may serve as a scaffold for important factors or co-factors 
for nucleolar function.  Whether Taspase1 activity is regulated is also an open matter, especially 
since Taspase1 seems to remain in the nucleolus in most situations, though preliminary evidence 
suggests that Taspase1 may re-localize given cellular stresses like DNA damage.  Other work 
from our laboratory indicates that Taspase1 shares an interaction with DDB1 and DNAPK, further 
implicating a role for Taspase1 responsiveness to DNA damage. 
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Murine models of tumorigenesis will elucidate mechanisms of Taspase1 addiction in cancer 
Examination of publicly available data from primary human samples provides some insight 
regarding which tumor types might depend on Taspase1 for continued propagation.  As our 
studies demonstrate, high basal Taspase1 expression in tumors correlates with the degree of 
their dependence on continued Taspase1 expression.  Though squamous carcinomas of the 
cervix and of the head and neck have markedly up-regulated Taspase1 expression, tractable 
murine models of tumorigenesis exist for blood tumors in which we have evidence that Taspase1 
is up-regulated.  This evidence was gathered from a study done by Radich and colleagues 
(Radich et al., 2006), which examined gene expression changes based on progression of CML 
from its indolent chronic phase, through the accelerated, and terminal blast crisis phases.  When 
examining Taspase1 expression in CML progression, a pattern emerges—that Taspase1 is 
expressed highly specifically in blast crisis cells (Figure 4.8). 
 
Because blast crisis is largely refractory to treatment, and because Taspase1 up-regulation 
suggests a developed dependence on its continued expression, we chose to examine its 
dependence on Taspase1 because it could potentially be an important tumor maintenance factor 
amenable to pharmacological inhibition.  Progression to blast crisis typically involves genetic 
alterations that complement the BCR/ABL oncogenic tyrosine kinase translocation, which drives 
proliferation through multiple effectors, including RAS and PI3K/AKT.  Most secondary mutations 
either directly or indirectly inactivate p53 or Rb, which have positive effects on survival and 
proliferation.  Yet, it is unclear what causes the loss of differentiation observed in blast crisis—
whether it is a proliferative expansion of undifferentiated blasts, or whether there is an active 
program causing de-differentiation (Calabretta and Perrotti, 2004).  However, there is evidence 
that a translocation associated, albeit at low frequency, with blast crisis—NUP98/HOXA9—can 
cause both proliferation and differentiation block of primary human CD34+ cells (Takeda et al., 
2006a).  When co-expressed with BCR/ABL in primary murine bone marrow, NUP98/HOXA9 
causes a short latency, de-differentiated, and transplantable leukemia reminiscent of human blast 
crisis (Dash et al., 2002; Neering et al., 2007). 
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We adopted this co-transduction model for our mice, which bear a conditional allele of Taspase1f/f 
as well as Cre-recombinase under the control of an interferon-responsive Mx1 promoter (Mx1-
Cre+;Taspase1f/f).  Bone marrow from conditional Taspase1 mice as well as control (Mx1-
Cre+;Taspase1+/+) mice were subjected to retroviral transduction with a virus encoding MSCV-
p210BCR/ABL and MSCV-NUP98/HOXA9-IRES EGFP (vectors courtesy of M. Tomasson, 
Washington University in Saint Louis) and transplanted into lethally irradiated recipient mice.  
Tumor latency for these primary recipients was around 17-21 days.  Spleens from primary 
recipient mice were analyzed for CD34+/c-Kit+ positive cells as well as absence of differentiated 
granulocytic or lymphoid markers (Mac1/Gr1 and B220/CD4/CD8, respectively), and comparable 
number of cells sorted for hematopoetic stem cell enriched immunophenotype (HSC, Lin-
/Sca1+/Kit+) were injected into sub-lethally irradiated mice to synchronize the onset of disease.  
One week after injection, poly-I-C injections were initiated to induce Taspase1 deletion, which 
was largely successful, as assessed by PCR genotyping. 
 
We were not able to resolve a survival difference between mice bearing Taspase1 deficient 
tumors and control.  However, in vitro culture of leukemic blasts from the spleens of the primary 
transplant (the same as used for secondary transplant, Figure 4.8) exhibited a decreased ability 
for Taspase1 deficient cells to survive in the long term.  Murine recombinant interferon β (mIFN-β) 
treatment was able to induce Taspase1 deletion in a fraction of cultured blasts, resulting in a 
decreased proliferation, increased cell death, and eventual loss of the Taspase1-deficient 
population (Figure 4.8).  Why there was a significant portion of cells that was not responsive to in 
vitro mIFN-β is unclear; however, that it took roughly 35 days for Taspase1-wild type blasts to 
fully out-compete Taspase1-null blasts suggests that Taspase1 deficiency causes leukemic 
blasts to be disadvantaged but is, alone, not sufficient to cause rapid death or severe proliferative 
block. 
 
Though in vitro data shows some anti-cancer effect in leukemic blasts in vitro, the failure to 
observe an extension in survival could be due to a variety of reasons.  Since Taspase1 deficiency 
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does not kill tumor cells rapidly, leukemic blasts may still proliferate sufficiently to overwhelm the 
host before a therapeutic effect can take place.  Alternatively, the secondary transplant may 
reflect a different kind of leukemia between the wild type control and the floxed conditional 
Taspase1 leukemia because pools of bone marrow are transduced, with transfection efficiencies 
that are roughly 5% for the GFP-tagged NUP98/HOXA9 and less than 0.1% likely transduced 
with both BCR/ABL and NUP98/HOXA9.  Thus, it is unclear which cell of origin gives rise to the 
observed leukemia. 
 
To address the first problem, serial transplant from secondary recipients to tertiary recipients may 
help resolve a difference between Taspase1-null leukemias and Taspase1-wild type.  As was 
observed in cancer cell lines, Taspase1 loss requires additional death stimuli to achieve an 
appreciable gain in cell death, and this may be the case in blast crisis leukemias as well.  Further 
characterization of BCL-2 family members, such as MCL-1 and BIM may provide insight into the 
possible molecular regulation of cell death in these cells, since changes in these proteins might 
dictate response to therapies like ABT-737 and imatinib.  Decreased proliferation may be evident 
by staining Taspase1-deficient cells to assess actively cycling cells, while probing for expression 
levels of known Taspase1 regulated genes Cyclins D, E, A, and CDKIs p16INK4A, p21CIP1, and 
p27KIP1.  BCR/ABL is known to repress p27KIP1 and p18INK4C through activation of the PI3K 
pathway (Gesbert et al., 2000), while our prior work demonstrates an inverse relationship 
between Taspase1 function and p27 expression. 
 
More recent studies using the BCR/ABL and NUP98/HOXA9 model of blast crisis have taken 
measures to ensure the generation of more homogeneous tumors.  Using a MSCV-BCR/ABL-
IRES-GFP co-transduced with MSCV-NUP98/HOXA9-YFP to isolated LSK cells allowed Jordan 
and colleagues to track and immunophenotype the leukemia initiating cells in this model as 
Lineage-/Kit+/Flt3+/Sca+/ CD34+/CD150- that are simultaneously GFP and YFP double positive 
(Neering et al., 2007).  Transduction of the LSK compartment of bone marrow limits the subtypes 
of cells that can give rise to leukemia, decreasing variability in the resultant phenotype. 
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4.3 Implications of non-oncogene addiction in cancer therapy 
 
Non-oncogene addiction 
Cancer cells exhibit deregulated signaling pathways with adaptations that overcome cellular 
safeguards that prevent oncogenic transformation.  This “intrinsic tumor suppression” represents 
a pleiotropic balancing act seen in much of biology, in this case with aberrant signaling eliciting 
biological countermeasures to maintain homeostasis (Lowe et al., 2004).  The product of 
tumorigenesis, then, is the phenotypic manifestation of accrued genetic and epigenetic changes 
that drive proliferative and survival signals, or that disarm the intrinsic anti-tumor responses.  The 
phenomenon of oncogene addiction suggests that perturbation of this balance can be 
catastrophic for the tumor cell, as the signaling pathways have re-wired themselves through the 
natural history of the genesis of the tumor to require persistent signaling to maintain unrestricted, 
malignant growth (Weinstein, 2000).  Though this is the concept underlying most of the current, 
successful targeted therapies, these therapies do not cure cancer, suggesting that just as 
cancers can evolve their signaling to accommodate increased proliferative drive against the 
balance of growth suppression and cell death, their addictions evolve away from particular apical 
oncogenes to other oncogenes that employ shared, or perhaps distinct, subordinate processes. 
 
Lindquist and colleagues described a rate-limiting factor in tumorigenesis—the heat shock factor 
1 (HSF1) transcription factor, which is required for efficient tumorigenesis and tumor 
maintenance.  Deficiency in HSF1 impaired chemical skin carcinogensis as well as a p53-mutant 
carcinogenesis in mice and prevented transformation of MEFs by the well-established oncogene 
PDGF-B.  Human cancer cell lines also depend on HSF1 for continued proliferation and survival, 
while normal fibroblasts did not, suggesting an increased reliance on HSF1 in cancer.  
Concordantly, HSF1 knockout mice were also overtly normal.  Lindquist and colleagues also 
demonstrated the involvement of HSF1 in a broad array of biological pathways, including glucose 
metabolism, PKA signaling, and protein translation.  Importantly, HSF1 over-expression did not 
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drive tumorigenesis, which, like Taspase1, excludes it as a classical oncogene (Dai et al., 2007a).  
Increased dependence on the normal functions of cellular non-oncogenes like HSF1 was termed 
“non-oncogene addiction” (Solimini et al., 2007).  Since tumors strongly enforce signaling to many 
biological processes, and thus can be thought of as cells in “overdrive,” this potentially implicates 
a large number of non-oncogenes which may be rate-limiting in the formation and maintenance of 
cancer. 
 
Two classes of non-oncogene addiction, and likely more 
The functions of HSF1 serve as a general paradigm for the action of non-oncogene addiction 
factors.  As a transcription factor responsive to proteotoxic stress, HSF1 contributes to heat 
tolerance through resolution of non-native protein stress.  Examination of other putative non-
oncogene addiction factors formed the basis for postulating two general classes of non-oncogene 
addiction—one which, as a result of deficiency in the non-oncogene, lowers the general threshold 
of stress resistance in a cell and one that increase cellular stresses to overwhelm the supportive 
networks in place to permit the inherently stressful cancer state.  Cancers are subjected, by their 
nature, to increased genotoxic, proteotoxic, oxidative, and metabolic stresses (Luo et al., 2009).  
Causing an imbalance in the stress state, as evidenced by HSF1 loss, can severely impede 
tumor growth.  Even dietary restriction alone, causing metabolic stress, can hamper growth in 
tumors that do not constitutively activate the PI3K pathway (Kalaany and Sabatini, 2009) 
 
Other non-oncogene addiction factors are readily discernable from the increased or altered 
normal cellular physiology adopted by the tumor.  A recent study demonstrated that ribosomal 
haploinsufficiency severely impaired MYC-mediated tumorigenesis.  Many cancers, to 
accommodate for increased proliferation and other cellular functions, have increased overall 
protein production as well as ribosome biosynthesis.  MYC has been described to be a master 
regulator of multiple aspects of ribosome biogenesis and translational control (Ruggero and 
Pandolfi, 2003).  Haploinsufficiency of ribosome subunit L24 caused total protein production to fall 
from its elevated state, when driven by MYC, to basal levels, which significantly prolonged the 
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latency to development of MYC-driven lymphomas (Barna et al., 2008).  An earlier study 
demonstrated, conversely, that increased expression of ribosomal subunit L11 provided a 
negative feedback signal that down-regulated MYC activity (Dai et al., 2007b), suggesting that in 
abnormally driven states, perturbation of up-regulated normal cellular functions (ribosomal 
biogenesis in this case) can have anti-tumor effects. 
 
Perhaps what substantiates the notion that non-oncogene addiction is relevant to cancer therapy 
is the clinical success of targeted inhibitors of the proteasome.  The proteasome performs the 
crucial function of protein turnover to alleviate any potential stress caused by accumulation of 
expired proteins, as well as allowing proper execution of biological cascades that depend on the 
periodic loss of signaling molecules.  Bortezomib, as discussed in Chapter 3, is a dipeptidyl 
boronic acid that inhibits the threonine protease function of the proteasome, which elevates the 
inhibitor of NF-κB, IκB, to prevent NF-κB-mediated activation of pro-cancer targets, including IL-6, 
Cyclin D1, and MYC (Hideshima et al., 2001).  Bortezomib has been used with clinical success to 
treat multiple myeloma (Shah and Orlowski, 2009) and a newer, cyclic peptide proteasome 
inhibitor Argyrin A has been demonstrated to inhibit cancer growth in a p27KIP1 dependent manner 
(Nickeleit et al., 2008). 
 
It is interesting to note that though multiple myelomas exhibit addiction to proteasomal function, 
the targets of proteasome inhibition, through stabilizing the majority of cellular proteins, include 
both oncogenes as well as tumor suppressors.  On the balance, however, proteasome inhibition 
exerts an anti-cancer effect.  It seems, then, that a third category of non-oncogene addiction 
exists—one which depends on the re-activation of latent tumor suppressive mechanisms or 
inactivation of oncogenes.  Argyrin A, as mentioned, has anti-cancer effects due to its 
stabilization of the cell cycle inhibitor p27, activating a latent tumor suppressor function.  IRF4 is 
an example of a non-oncogene addiction factor causing the down-regulation of oncogenic 
function in multiple myeloma.  IRF4 is a transcription factor involved in the maturation of antigen-
stimulated B-cells to plasma cells.  In multiple myeloma, IRF4 was demonstrated to participate in 
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a positive feedback cycle with MYC, though the repertoire of its function is broad—ranging from 
cell cycle regulation, metabolic control, membrane biogenesis, cell death, and differentiation.  
IRF4 depletion breaks this feedback and was lethal to multiple myeloma cells.  Consistent with its 
role as a non-oncogene addiction factor, its loss had little effect on normal blood cells (Shaffer et 
al., 2008; Shaughnessy, 2008). 
 
Taspase1 as a non-oncogene mediator of tumorigenesis and maintenance 
Taspase1, much like IRF4, is a non-oncogene addiction factor that regulates tumor suppressor 
and oncogene functions.  Taspase1 also orchestrates multiple developmental processes through 
its proteolytic regulation of MLL, which in turn maintains proper HOX gene expression.  Taspase1 
targets TFIIA and ALF also are general transcription factors likely involved in other important 
developmental processes (S. Sasagawa, unpublished data).  This and the possibility that there 
are other substrates awaiting description intimates a substantial and complex repertoire of 
Taspase1 function.  This is in keeping with current non-oncogene factors described, which are 
generally transcription factors (IRF4, HSF1) or members of normal cellular machinery with very 
general functions (the ribosome and proteasome).  It is possible that this is coincidence, or that 
too few non-oncogene addiction factors have been validated.  Alternatively, there may be some 
underlying reason that cells become addicted to these discreet molecular nodes that integrate 
broad-ranging inputs and effectors. 
 
It is possible that the plasticity of the inputs and effectors for non-oncogene addiction factors 
obviates the need for tumors to select genetic mutants, because these factors are so pliable that 
their tumorigenic outputs are but extensions of their normal day jobs.  Though they are 
subordinate to oncogene signaling, the transformed state still depends on the continued function 
of these pieces of normal cellular machinery and will depend on them to a higher degree than 
non-transformed cells.  Yet, it may also be an eventuality that cancer, since it is a dynamic and 
evolving organism, will find a way to circumvent reliance on non-oncogene addiction factors in a 
similar way it divorces itself from apical oncogenes (Merlo et al., 2006).  It has been suggested 
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then, as demonstrated in the case of Taspase1 inhibition (Figure 2.11), that additional 
“orthogonal” treatments will bolster therapeutic effects of non-oncogene addiction targeting (Luo 
et al., 2009).  To this end, we have demonstrated that DNA damaging agents as well as the BCL-
2/BCL-XL-targeted chemotherapeutic ABT-737 cooperate strongly with Taspase1-deficiency to kill 
the glioblastoma cell line U251 in vitro and in vivo. 
 
Our studies demonstrate that Taspase1 coordinates both proliferation and apoptosis in cancer 
cell lines via its regulation of p27KIP1 and MCL-1, respectively.  We have also found that human 
tumors over-express Taspase1 likely reflecting an increased reliance on its function.  Further, we 
show that the bioactive small molecule TASPIN-1 demonstrates specific Taspase1 inhibition and 
anti-tumor effects in vitro in breast adenocarcinoma and glioblastoma cell lines, and in vivo in 
murine tumor models.  Together, this body of work places Taspase1 firmly as a promising drug 
target for cancer therapy, warranting further study of Taspase1 regulation and other Taspase1 
effector functions, as well as the characterization and modification of new and current Taspase1 
inhibitors for therapy in cancer patients. 
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4.4   Figures 
 
 
 
 
 
 
 
Figure 4.1.  Taspase1 coordinates proliferation and apoptosis through its regulation of Cyclin-
dependent kinase inhibitors (CDKIs), Cyclins, and MCL-1. 
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Figure 4.2.  Primary MEFs are not sensitized to cell with Taspase1 deficiency. 
 
A, Cell death was determined by Annexin V-Cy3 staining of primary MEFs subjected to various 
the following death stimuli – 24h detachment in 1% serum (anoikis), 24h in 100μg/mL etoposide, 
and 24h in 2μM doxorubicin.  Control cells were adherent cells analyzed 24h after plating.  B, 
Western blot analysis of pro-apoptotic BH3-only proteins Bid, Bim, and PUMA and anti-apoptotic 
MCL-1, BCL-XL, and BCL-2.  Equal protein loading was determined by β-Actin immunoblot. 
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Figure 4.3.  Transformed clones up-regulate Taspase1 expression 
 
A, Primary MEFs were transduced with retroviruses encoding the oncogene pairs indicated.  
Immunoblot compares expression of Taspase1 in primary MEFs to oncogene transduced MEFs 
prior to soft agar selection.  B, Western blot analysis of Taspase1 expression in primary MEFs 
compared to clones selected for their survival in soft agar culture. 
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Figure 4.4.  Taspase1 expression is up-regulated in subsets of blood tumors. 
 
A, Taspase1 transcript from human leukemias designated by their FAB subtype.  B, MLL1 
transcript from human leukemias designated by their FAB subtype.  Data courtesy of T. Ley and 
N. Grieselhuber. 
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Figure 4.5.  Taspase1 is over-expressed in human breast cancer. 
 
A, Immunofluorescence analysis of Taspase1 in breast cancer (left panels) and histologically 
normal ducts (right panels).  Taspase1 was detected using a polyclonal antibody raised against 
Taspase1 (DF380, Alexa-488, green), as well as nucleolar antigen C23 (Alexa-568, red), and 
DAPI (blue) for nuclei.  The top two panels are Taspase1 staining alone, and the bottom two are 
merged red, green, and blue images.  B, Breast cancer stained with a monoclonal antibody 
raised against Taspase1 (9G1D1, Alexa-488, green).  Fluorescence intensity was quantified and 
compared between histologically normal and tumor tissue within the same section.  The mean 
intensity is 1.31 (1.19-1.518, 95% CI), where intensity of normal tissue = 1.  
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Figure 4.6.  Taspase1 is over-expressed in human colon cancer. 
 
Immunofluorescence analysis of Taspase1 in colon cancer was performed using a monoclonal 
antibody raised against Taspase1 (10H2F6, Alexa-488, green).  Fluorescence intensity was 
quantified and compared between histologically normal and tumor tissue within the same section.  
The mean intensity is 1.94 (1.34-2.55, 95% CI), where intensity of normal tissue = 1.  
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Figure 4.7.  Taspase1 is highly expressed in human melanoma. 
 
A, Immunofluorescence analysis of Taspase1 in melanoma was performed using a polyclonal 
antibody raised against Taspase1 (DF380, Alexa-488, green).  Melan-A was detected using a 
monoclonal antibody (Alexa-568, red), and nuclei were visualized by DAPI stain (blue).  B, Melan 
A staining of malignant melanocytes was performed by immunoperodxidase development of DAB 
(brown).  Taspase1 was visualized by staining with a monoclonal antibody against Taspase1 
(10H2F6, Alexa-488, green). 
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Figure 4.8.  A murine model for Taspase1-dependence in CML blast crisis. 
 
A, A schematic representation of the blast crisis model, comparing tumors derived from donor 
bone marrow from Mx1-Cre wild type and Taspase1f/f mice.  B, Taspase1 transcript level from a 
study of 57 cases of chronic phase CML, 17 cases of accelerated phase, and 37 cases of blast 
crisis CML done by Radich, et al.  Taspase1 is overexpressed in blast crisis (p=3.45x10-9, 
statistics from www.oncomine.org).  C, Primary transplant cells were cultured with a 2 day puls of 
1000U/mL murine IFN-β in IMDM/15% FBS/50nM β-mercaptoethanol supplemented with 
10ng/mL IL-3, 10ng/mL IL-6, and 100ng/mL SCF.  Cre-mediated Taspase1 deletion was 
assessed by PCR.  D,  Continued culture of blast crisis cells of indicated treatment and genotype 
were counted by Hemavet 950 (Drew Scientific, Dallas, TX).  E, Cell death in continuous culture 
was determined by trypan blue exclusion. 
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Accession TF name TF gene ID Symbol P-value 
MA0058 Max 
  
0.0003 
M00118 c-Myc:Max 4149 MAX 0.0005 
M00118 c-Myc:Max 4609 MYC 0.0005 
M00960 PR, GR 5241 PGR 0.0007 
M00960 PR, GR 2908 NR3C1 0.0007 
M00799 Myc 4149 MAX 0.0009 
M00799 Myc 4609 MYC 0.0009 
M00473 FOXO1 2308 FOXO1A 0.002 
MA0093 USF 7391 USF1 0.0021 
MA0059 Myc-Max 4609 MYC 0.0035 
M00472 FOXO4 4303 MLLT7 0.0036 
M00236 Arnt 405 ARNT 0.0066 
 
 
 
 
 
 
 
 
 
Table 4.1.  Promoter analysis pipeline analysis of the Taspase1 promoter. 
 
Promoter analysis pipeline (PAP, http://bioinformatics.wustl.edu/webTools/Home Action.do) 
analysis of conserved transcription factor binding sites between mouse and human Taspase1 
promoters. 
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